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attention: Technologies, Standards and Norms (TSN). Comments may also be submitted 
electronically to the Responsible Officer:  Dr C Micha Nübling at email: 
nueblingc@who.int. 
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Summary 
 
A WHO international collaborative study was undertaken to evaluate preparations of Ebola 
virus disease (EVD) convalescent plasmas for their suitability to serve as the WHO 1
st
 
International Standard (IS) and the WHO 1
st
 International Reference Panel (IRP) for Ebola 
virus antibodies for use in the standardization and control of assays. The study involved 
participants testing the convalescent plasma sample preparations and additional monoclonal 
antibody samples in a blinded manner alongside the WHO International Reference Reagent 
(NIBSC code 15/220) using anti-EBOV assays established in their laboratories. 
 
The candidate 1
st
 IS for Ebola virus antibodies (study sample code 92, NIBSC 15/262) 
consists of ampoules containing the freeze-dried equivalent of 0.5 mL pooled convalescent 
plasma obtained from six Sierra Leone patients recovered from EVD. The candidate 1
st
  IRP 
of anti-Ebola virus convalescent plasmas (NIBSC 16/344) consists of freeze-dried 
preparations of single donations of convalescent plasma obtained from four patients and one 
healthy blood donor. Each panel member is an ampoule containing the equivalent of 0.25mL 
plasma. All convalescent plasmas are confirmed PCR-negative for Ebola virus and 
underwent, along with the negative plasma, solvent detergent (SD) treatment prior to their 
development into candidate WHO biological reference materials. 
 
In this collaborative study, 17 laboratories from 4 countries used a range of live Ebola virus 
neutralization assays, pseudotyped virus neutralisation assays and enzyme immunoassays to 
test the collaborative study samples. Surface plasmon resonance and Western blot 
assessments were also undertaken. 
 
The study found that the candidate International Standard has the highest absolute titre 
among the convalescent plasma samples, although the geometric mean titres of all the 
convalescent plasmas fall within ~5-fold of each other. The potencies of three of the 
convalescent samples fall near the detection limit of some assays. This study also 
demonstrated that the agreement between laboratories for potencies relative to the candidate 
International Standard represents an improvement compared to the agreement in absolute 
titres; however, there is poor agreement between relative potencies for some assays. The 
results obtained from accelerated thermal degradation studies at 1year indicate that the 
candidate IS is stable and suitable for long-term use. 
 
The results of the collaborative study indicate the suitability of the candidates to serve as 
WHO reference materials and it is proposed that 15/262 is established as the WHO 1
st
 IS for 
EBOV antibodies with an assigned potency of 1.5 IU/mL when reconstituted as directed in 
the instructions for use. It is also proposed that 16/344 is established as the WHO 1
st
 IRP of 
anti-EBOV convalescent plasmas with panel member code 95 (NIBSC 15/280) assigned a 
unitage of 1.1 IU/mL when reconstituted as directed in the instructions for use. The other 
panel members have not been assigned a unitage. 
 
The implementation and use by laboratories of the proposed WHO reference materials for 
EBOV antibodies will facilitate the characterization of the factors that contribute to assay 
variability and standardization of results across assays and laboratories. 
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Introduction 
 
The WHO Expert Committee on Biological Standardization (ECBS) is the scientific body 
that establishes WHO biological reference standards which serve to define an internationally 
agreed unit to allow comparison of biological measurements worldwide. WHO International 
Standards (IS) for biological substances are recognized as the highest order of reference 
materials for biological substances and they are assigned potencies in International Units 
(IU). International Standards are used to quantify the amount of biological activity present in 
a sample in terms of the IU, making assays from different laboratories comparable. This 
makes it possible to better define parameters such as the analytical sensitivity of tests or 
clinical parameters such as protective levels of antibody [3]. Another class of WHO 
biological reference standard is the International Reference Reagent (IRR). WHO IRRs do 
not carry the designation of ISs, but are nevertheless of great value in the standardization of 
assays applied to biological products and diagnostic materials. 
 
In October 2015, the WHO ECBS established a preparation of plasma (NIBSC product code 
15/220) obtained from a patient recovered from Ebola virus disease (EVD) to serve as the 
WHO 1
st
 IRR for Ebola virus (EBOV) antibodies with an assigned potency of 1 unit per mL. 
NIBSC 15/220 was assessed in a WHO international collaborative study and is known in that 
study as EBOV Ab Sample Code 79 [1].  
 
15/220 has been serving as the interim WHO biological reference standard for EBOV 
antibodies 
(https://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=15/220) 
while further work was undertaken to develop EVD convalescent plasma samples for use as 
WHO IS and as members of an IRP for EBOV antibodies. This report describes the 
preparation and international collaborative study evaluation of candidate convalescent plasma 
preparations to serve as the WHO 1
st
 IS and members of the 1
st
 IRP for EBOV antibodies for 
use in the calibration and control of assays. The study involved testing eight blinded EBOV 
antibody samples alongside the WHO IRR (15/220) in assay(s) that are in routine use in 
participants’ laboratories. 
 
Aims of study 
 
The aims [2] of this WHO international collaborative study are to  
 assess the suitability of the candidate to serve as the 1st International Standard for 
EBOV antibodies with an assigned unitage in IU per ampoule for use in the 
harmonization of EBOV antibody assays. There is no international conventional 
reference measurement procedure for EBOV antibodies and the IU is not traceable to 
the International System of Units (SI) of quantity. 
 identify additional candidate EBOV antibody preparations for inclusion in a WHO 
International Reference Panel for EBOV antibodies.  
 characterise each candidate preparation in terms of reactivity/specificity.  
 assess each candidate’s potency i.e. readout in a range of typical assays performed in 
different laboratories. 
 assess commutability i.e. to establish the extent to which each candidate is suitable to 
serve as an International Standard for the variety of different samples and assay types. 
 advise WHO ECBS on the establishment of the candidate found to be suitable to serve 
as the 1
st
 International Standard. 
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 advise WHO ECBS on the establishment of the WHO 1st International Reference 
Panel of Anti-EBOV Convalescent Plasma. 
 
Materials and Methods 
 
Source materials 
Prior to shipment to the UK, all convalescent plasmas were tested and found negative for 
EBOV RNA. Prior to receipt at NIBSC, the convalescent plasmas were held at Public Health 
England (PHE), Colindale, UK until confirmed by PCR that no EBOV RNA could be 
detected in the materials. After receipt at NIBSC, plasma donations and the negative plasma 
samples were SD-treated as described previously [1]. 
 
Candidate 1
st
 WHO International Standard for antibodies to EBOV 
The candidate material is a freeze-dried preparation of a pool of plasmas obtained from six 
Sierra Leone (SL) patients recovered from EVD (provided by Dr Calum Semple, University 
of Liverpool, UK, through the auspices of the Ebola Convalescent Plasma (CP) Consortium) 
(Appendix 2). The treatment histories of the Sierra Leone patients are not known. 
Approximately 1000 ampoules containing the freeze-dried equivalent of 0.5 mL pooled 
plasma were prepared at NIBSC. 
 
Candidate WHO International Reference Panel Samples for EBOV antibodies 
The candidate panel members are freeze-dried preparations of EVD convalescent plasma 
samples obtained from four patients and a negative control plasma. One convalescent plasma 
donation was obtained by the National Institute for Infectious Diseases Lazzaro Spallanzani, 
Italy (INMI) (provided by Dr. Antonino Di Caro). The INMI patient had received Favipiravir, 
3 treatments of convalescent plasma from 2 donors, ZMAb and Melanocortin (TCS 10). 
Convalescent plasmas obtained by Oslo University (NOR), the American Red Cross (ARC) 
and the UK National Health Service Blood and Transplant (NHSBT) have been described 
elsewhere [1]. Briefly, the Ebola-specific therapeutic treatments given to the NOR patient 
include ZMAb, Favipiravir and TKM-100802. The ARC patient received 2 aliquots of 
convalescent plasma 24 hours apart, as well as 7 nightly infusions of TKM-Ebola. The ARC 
donor did not receive monoclonal antibody treatments. The NHSBT patient received 
Brincidifovir and convalescent plasma treatments. 
 
Approximately 200 to 300 ampoules containing the freeze-dried equivalent of plasma were 
prepared for each panel member. Note that while the NOR, ARC and NHSBT source 
materials listed above are the same as those described in the 2015 ECBS report [1], they have 
been prepared independently for assessment in this collaborative study. For example, the 
NOR, ARC and NHSBT samples for this collaborative study have undergone separate SD 
treatments with respect to Sample 43, 79 and 28 from the 2015 study. Furthermore, these 
samples have been freeze-dried for this collaborative study, whereas the corresponding 
samples in the earlier study are liquid presentations.  
 
Monoclonal antibodies 
Purified monoclonal antibodies (MAbs) (donated by Prof A. Townsend, University of 
Oxford, UK) were cloned from B cells of volunteers participating in the Oxford, UK vaccine 
trial who were primed with the monovalent formulation of the chimpanzee adenovirus 3 
(ChAd3)-vectored vaccine encoding the surface glycoprotein of Ebola virus (GSK/NIH 
vaccine candidate) [3]. Two MAbs have been formulated in sterile PBS-Ca2+-Mg2+ 
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supplemented with 5% human serum albumin. One-hundred vials of each MAb in 100µL 
liquid aliquots were prepared. 
 
Coded study samples 
Table 1 lists the collaborative study samples. The samples were shipped under NIBSC 
dispatch reference CS570. 
 
Study protocol 
The final version of the study protocol is given in Appendix 3. In brief, participants were 
requested to test the samples using their established method(s) for the detection of antibodies 
to EBOV. Participants were asked to perform 3 independent assays on different days. An 
Excel reporting sheet was provided with suggested dilutions for assaying each study sample.  
For each assay, participants were requested to make 2 independent series of dilutions of the 
study samples, and assay all samples concurrently if feasible. Participants were requested to 
record in the reporting sheet all essential information including the raw data from each assay.  
Participants were requested to return results within 6 weeks of receipt of materials. 
 
Participants 
Twenty laboratories took receipt of study samples and seventeen laboratories returned results. 
The participants were from France (1), Germany (2), UK (4) and USA (10). All laboratories 
are referred to by code number allocated at random and not representing the order of listing in 
Appendix 1. Participating organisations include government research, public health, medical 
counter-measure and regulatory organisations; university and research organisations; 
developers of biologics, assays and reagents and providers of laboratory services for vaccine 
trials.  Three laboratories reported that they have BSL4 containment facilities for handling 
Ebolavirus.  
 
Assay methods  
Assays used by participants are summarised in Table 2.  Where laboratories performed 
multiple assay methods, laboratory codes are followed by a letter indicating the different 
methods e.g. lab 10a, 10b.  The assay methods fall into 3 general categories: neutralization of 
live Ebola virus (Neut); neutralization of Ebola pseudotypes (PsN); and enzyme 
immunoassays (EIA). Surface plasmon resonance (SPR) and Western blot assessments were 
also undertaken in the study. 
 
Statistical methods  
For Neut and PsN assays, median endpoint titres or reduction neutralization titres (RNT) 50 
were calculated when more than half of the reported results indicated a positive response for 
that sample. Relative potencies were reported against sample 92 (the candidate WHO IS, 
NIBSC code 15/262) and sample 15/220 (the current WHO IRR). 
 
Enzyme immunoassay data were analysed using a parallel line or sigmoid curve model with 
untransformed or log transformed responses. Calculations were performed using the EDQM 
software CombiStats Version 5.0 [4]. Model fit was assessed visually and non-parallelism 
was assessed by calculation of the ratio of fitted slopes for the test and reference samples 
under consideration. The samples were concluded to be non-parallel when the slope ratio was 
outside of the range 0.80 – 1.25 and no estimates are calculated in such cases. For each 
sample, relative potency estimates from all valid assays within laboratories were combined to 
generate an unweighted geometric mean (GM) for each laboratory, with these laboratory 
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means being used to calculate overall unweighted geometric means for each sample. 
Variability between assays within laboratories and between laboratories are expressed using 
geometric coefficients of variation (GCV = [10
s
-1]×100% where s is the standard deviation 
of the log10 transformed GM estimates). 
 
Stability study 
 
Ampoules of the candidate IS 15/262 have been placed at -20˚C, +4˚C, 37˚C, 45 ˚C and 
56 ˚C and will be retrieved at specific time points for assessment. To date, accelerated 
degradation data has been obtained for the 1 year time-point. The degradation samples were 
assayed concurrently using an in-house neutralization assay based on pseudotyped lentiviral 
vector particles [5]. The stability of the candidate IS was assessed using the Arrhenius model 
for accelerated degradation studies with potencies expressed relative to the samples stored at 
-20˚C [6, 7]. 
To limit the number of ampoules consumed in stability testing of individual panel members, 
the predicted stability of the candidate IRP is inferred from the stability of the candidate IS. 
 
Results and data analysis 
 
Production of candidate WHO 1
st
 IS and 1
st
 International Reference Panel 
members for EBOV Ab 
In January and March 2016, NIBSC filled and freeze-dried the candidate reference materials 
using documented procedures. The product summaries for the candidate IS (NIBSC code 
15/262) and IRP members (NIBSC codes 15/280, 15/284, 15/286, 15/288) are shown in 
Table 3. To limit the number of ampoules consumed in quality control testing, the negative 
plasma sample (15/288) was used as a surrogate for determining the dry weight, moisture and 
oxygen content of the candidate IRP as a whole. The % coefficient of variation (CV) of the 
fill mass for all products and the mean residual moisture of the candidate IS and negative 
panel member were within acceptable limits for a WHO IS [2]. The residual oxygen content 
of the candidate IS and negative panel member fell within the NIBSC working limit of 1.1%. 
Currently there are approximately 1000 ampoules of 15/262 and 100 ampoules of each of the 
reference panel members available for issue. 
 
Prior to their dispatch to the participating laboratories, the reactivities of the freeze-dried 
candidates and MAb preparations were confirmed at NIBSC using the in-house pseudotype 
neutralization assay [5]. 
 
Collaborative study data received 
Seventeen laboratories returned data sets for 26 assay methods (Table 2). Two labs (15b, 16a) 
returned data for live virus neutralization assays performed under BSL4 containment. Seven 
laboratories reported results for pseudotype neutralisation assays using lentiviral vectors 
(LVV) (labs 2, 4, 9, 11) or vesicular stomatitis virus vectors (VSV) (10b, 12, 13). Ten labs 
returned data for fifteen EIA-based methods (1a, 1b, 1c, 1d, 3, 5, 6a, 6b, 6c, 7, 8, 10a, 14, 
15a, 16b). Laboratory 6 also provided Western blot analyses of the study samples. Laboratory 
17 provided results for their SPR method. 
 
Where applicable, all laboratories used buffer-based diluents to prepare sample dilutions. 
Examples of diluents used are “buffer”, “commercial” or “kit” sample buffer, “transport 
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medium”, DMEM, DMEM + 1% FBS, PBS + 3% or 5% non-fat milk + 0.1 or 0.05% Tween; 
PBS + 2% FCS or 1% milk, EME + 10% FBS, “cell culture medium”, SF medium. 
 
Laboratory 1 indicated that their EIA methods are not amenable to parallel line analysis. For 
method 1a, study samples were diluted 1:4 in commercial sample diluent prior to testing. As 
this is a screening assay, samples were not tested in duplicate and no serial dilutions were 
performed. For method 1b, study samples were diluted 1:50 in commercial sample diluent. 
No serial dilutions were performed and samples were tested in duplicate. Results listed as 
‘ND’ are samples that were ‘reactive’ by method 1a, but have a ‘titre’ too low to be detected 
by method 1b. For method 1c, study samples were tested ‘neat’ and not in duplicate. For 
method 1d, routine plasma samples are usually tested at 1:200 dilution with in-house 
transport medium. For the collaborative study, serial dilutions of samples in duplicate were 
performed prior to testing. 
 
Laboratory 2 experienced some pipetting problems due to viscosity of some samples. 
Concentration-dependent inhibition was noted for some samples. 
 
Laboratory 6 returned an overall result of negative for sample 39. As for the previous study, 
the NP antigens do not differentiate between exposure to SUDV and EBOV as the EBOV 
convalescent plasmas have reactivities against SUDV NP in both ELISA and Western blot 
analysis. The Western blot analysis of the samples for antibodies against EBOV GP-1 
isoform, EBOV GP-1, 2 isoform, EBOV NP, SUDV GP and SUDV NP is shown in 
Appendix 4. 
 
Laboratory 10 provided some details of their experience with testing the samples by ELISA 
(method 10a) and rVSV EBOV GP PsN (method 10b) (See Appendix 5). For the rVSV PsN 
it should be noted that although the assay does begin at a 1:10 dilution of sample, the 
PRNT60 results start at the 1:20 dilution and exclude the initial 1:10 dilution due to a “plaque 
explosion phenomenon” that has been seen in the assay where there is an excessive number 
of plaques in the first dilution only. 
 
Laboratory 11 stated that for their LVV PsN, samples 38, 66 and 95 gave dilution curves that 
were hard to interpret in the first set of testing.  They tried slightly different approaches for 
the second and third set of assays with no resolution of the issue. 
 
Laboratory 12 reported samples 38, 66, and 85 as negative or marginally positive stating that 
FRNT (Fluorescence Reduction Neutralization Titre) results could not be determined for 
these samples. 
 
In addition to the raw data readouts, laboratory 13 provided their PsVNA50 and PsVNA80 
data in graphical form (Appendix 6). 
 
Laboratory 15 provided tables and a summary of results by ELISA (method 15a) and FRNA 
(method 15b) (Appendix 7). Samples were not heat inactivated prior to use. During sample 
dilution, it was noted that the reconstituted samples were viscous after incubation. It is 
unclear if this will impact the results from different assays. 
 
Laboratory 16 provided graphs comparing the endpoint titres obtained with their 
neutralisation assay against live EBOV/Mayinga (method 16a) and reactivities at dilution 
obtained in their EIA against inactivated EBOV/Makona (16b) (Appendix 8). 
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Laboratory 17 provided raw data readouts for SPR. (Appendix 9). 
 
Scoring study samples as reactive for Ebola virus antibodies 
 
Plasma sample reactivities 
The scorings of the samples as positive or negative for EBOV antibodies are shown in Table 
4. Having come from a healthy blood donor in the UK, sample 39 is expected to be negative. 
The EVD convalescent patient samples (15/220, 38, 66, 85, 92, 95) have previously been 
shown to be positive for antibodies to EBOV. 
 
Participants were requested to include the cut-off value indicating sero-reactivity for each 
assay and to indicate whether each sample dilution tested is considered positive or negative 
according to their criteria. The methods that returned the expected results for reactivity of the 
plasma samples are 16a (Neut), 4 (LVV PsN), 10b, 13 (VSV PsN), 1a, 1c, 1d, 3, 5, 7, 8, 14, 
15a and 16b (EIA) and 17 (SPR) (Table 4). 
 
Convalescent plasma samples 38, 66 and 85 were scored negative in at least one assay using 
method 15b (Neut) or 12 (rcVSV-PsN). The quantitative EIA method 1b did not detect 
EBOV antibodies in samples 38 and 85 at the single 1/50 dilution tested. These results may 
be a reflection of assay sensitivity as commented by the participants above. 
Laboratories 2, 9, 11 (LVV-PsN), 6a, 6b, 10a, (EIA) scored the negative sample 39 as 
positive in at least 1 assay, but otherwise correctly scored the convalescent plasmas as 
positive (Table 4). 
 
As reported previously, the NP-based assays used by laboratory 6 did not differentiate 
between Sudan ebolavirus and EBOV antibodies [1]. The Western blots provided by 
laboratory 6 demonstrate that the convalescent plasma samples are reactive against both 
vaccine and non-vaccine EBOV antigens (G and NP) while the negative sample is confirmed 
non-reactive (Appendix 4). 
 
MAb reactivities 
The monoclonal antibody preparations (samples 93 & 94) are clonally derived from 
recipients of a vaccine encoding the GP of EBOV and are expected to be reactive against GP 
only. They have not been extensively characterised. It is therefore not known how they may 
perform in assays. 
 
Laboratories that scored both MAb samples as positive are 16a (Neut); 10a, 11, 12, 13 (PsN); 
1a, 1d, 4, 5, 6a, 8 and 14 (anti-GP EIA).  
 
Methods that scored both MAb samples as negative include two anti-GP EIA (1c and 2) and 
an EIA based on inactivated whole virus coated onto plates (3). Also, as expected, the 
monoclonal antibodies were not detected using methods that did not target antibodies against 
the G protein (EIA methods 6b, 6c, 7). 
 
Methods that scored MAb sample 93 overall as positive and 94 as negative are one Neut 
(15b), one LVV PsN (9), two EIA (15a, 16b) and the SPR (17). Laboratory 16 commented 
that, with the exception of sample 94, their ELISA and Neut data correlated well with each 
other. They concluded that sample 94 antibodies most likely recognize conformation-
dependent epitopes that are sensitive to SDS and heat treatment. 
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Laboratory 10b was not able to obtain consistent results for samples 93 and 94 due to flat 
titration curves as explained in Appendix 5. 
 
There were no cases where a laboratory reported sample 93 as negative and sample 94 
positive. 
 
Neut and PsN assays  
Table 5 shows individual assay results along with the median titre estimates for Neut and 
PsN. The median titre values are also expressed relative to sample 92 (the candidate WHO 
IS) and sample 15/220 (the current WHO IRR). The EBOV variant, if known, is also given 
for the challenge virus or antigen used. For the convalescent plasma samples, Tables 6-8 
summarise the individual laboratory estimated median titres (Table 6), the geometric mean 
(GM) potencies relative to sample 92 (Table 7) and sample 15/220 (Table 8). Tables 6-8 also 
show the overall GM and inter- laboratory geometric coefficient of variation (GCV), which 
measures variation across laboratories and methods. 
 
Absolute antibody titres for EBOV in convalescent plasma samples by Neut and PsN 
Individual laboratory estimated median titres for the convalescent plasma samples are shown 
in Table 6. Within laboratories, the titres for sample 15/220 and sample 95 are consistent to 
within a dilution step which is expected for samples derived from the same donated plasma. 
There are large differences observed between laboratories with, for example, titres ranging 
from 160 to 5230 for sample 15/220 and 28 to 7241 for sample 66. Part of the reason for 
these inter-laboratory differences may be differences in assay design and dilution series used. 
Some laboratories adjusted their dilution range or assay conditions between assays. Other 
laboratories had pipetting difficulties due to sample viscosity or other technical issues. 
 
The calculated geometric means for the convalescent plasma samples are also shown in Table 
6. At a titre of 529, the candidate IS (sample 92) has the highest titre, although the GM titres 
of all the convalescent plasmas fall within ~5-fold of each other. 
 
Enzyme immunoassays and surface plasmon resonance analysis 
Table 9 lists the individual EIA potency estimates relative to sample 92 using parallel line 
analyses. Table 9 also lists the cases where samples could not be assessed due to assay 
invalidity or other factors. Table 10 shows individual laboratory GM potencies for samples 
relative to sample 92 along with intra-laboratory GCV, which measures variation within a 
given laboratory. Overall GM and inter-laboratory GCV are also given in Table 10 for all 
targeted analytes tested by EIA (i.e. antibodies against G, NP and VP40) as well as for anti-G 
EIA only.  
Table 11 summarises the potency estimates relative to sample 15/220 for samples as 
described above for Table 10. 
Table 12 summarises the relative potency estimates of samples tested by SPR. 
 
Anti-EBOV potencies relative to candidate IS sample 92 
Overall geometric mean potencies of convalescent plasma samples 
The overall GM potency of the current WHO IRR (sample 15/220) relative to the candidate 
IS (sample 92) is 0.87 for neutralization-based assays (Table 7) and 0.52 for EIA (Table 10). 
With an overall potency of 0.81 for neutralization-based assays and 0.70 for EIA, the ARC-
derived sample 95, is close to that of the related IRR (Tables 7 and 10). The other three 
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convalescent plasmas (samples 38, 66, 85) have overall GM potencies that are lower than that 
of either the ARC samples or the candidate IS (Tables 7-8 and 10-11). 
 
The overall GM relative potencies across all assay methods are shown in Table 13.  
If the unitage of the WHO IRR, as established by ECBS, is maintained at 1 unit/mL, then the 
overall GM potency of the candidate IS has a nominal value of 1.5. In turn, the ARC-derived 
sample 95 has an overall GM potency of 1.1 relative to the candidate IS. 
 
The ranking of samples in terms of relative potency across all assay methods is 
92>95>15/220. The other convalescent plasmas (samples 38, 66, 85) are ranked as having 
lower relative potencies, but with no clear order of ranking.  
 
Inter-laboratory variability of convalescent plasma samples 
Comparing the overall GCVs in Tables 6 and 7, the variability between laboratories is 
reduced when neutralisation titres are expressed relative to the candidate IS sample 92. Using 
sample 92 as the reference, there is better agreement between laboratories for the EIA (GCV 
range 41% to 92%; Table 10) than for the neutralisation-based assays (GCV range 37% to 
292%; Table 7). Using the IRR sample 15/220 as a reference also improves agreement 
between laboratories but generally not to the same extent as that observed for sample 92 
(Tables 6-8 and 10-11). 
 
Intra-laboratory variability of convalescent plasma samples 
The GCVs shown in Table 10 for EIA are an indication of intra-laboratory variability for 
potencies relative to the candidate IS (rather than for the absolute titres).  The figures for 
individual laboratories and samples are based on only two or three assays however, and are 
sensitive to any variation in a single assay dose-response, or even a single response. Some 
assay methods could not be assessed for GCV as indicated in Table 9. Not all laboratories 
were using assays that had been optimised for parallel-line analysis and potency estimation, 
and any high intra-laboratory variability may not reflect the assay performance for detection 
of EBOV antibodies as positive or negative. 
 
Monoclonal antibody samples 
The interlaboratory agreement for the MAb samples 93 and 94 is not very satisfactory 
(Tables 5, 9-11). For example, the neutralisation titre estimates for sample 93 across 
laboratories range from 58 to 9632 (Table 5) with an overall GCV of 380% (results not 
shown). Also, relative potencies for sample 93 could only be determined from 4 of the 10 
EIA that reported the sample as positive (Table 10). The reasons for the poor agreement 
between laboratories for the MAbs may include those given above for the plasma samples, 
but also, the variability may be a reflection of the MAb preparations themselves (e.g. dilution 
effects of high titred antibody sample; epitope conformation and specificity). Although MAb 
samples 93 and 94 may have utility as reagents, further characterisation is required in order to 
fully understand their reactivity in EBOV Ab assays and they are not considered further in 
this report. 
 
Stability studies 
Accelerated degradation studies were undertaken on the candidate 1
st
 WHO IS 15/262.  
Samples of the candidate were stored at varying temperatures of -20ºC, +4ºC, +20ºC, +37ºC, 
+45ºC and +56ºC for a period of approximately1 year. The potency of samples of the 
candidate IS 15/262 stored at the elevated temperatures were expressed relative to the 
material stored at –20ºC.  The results of individual assays are summarized in Appendix 10. 
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The long-term stability of the candidate IS 15/262 was predicted using the Arrhenius model, 
using all temperatures up to +56°C, which gave a statistically good fit to the data.  The predicted 
percentage loss at 2, 4, 13, 26 and 52 weeks at the different temperatures of storage, is also 
shown in Appendix 10. The predictions are dependent on the estimated potencies at +37ºC and 
above being reliable, and the apparent drop in potency not being affected by problems of 
reconstitution.  This was seen with +45ºC and +56°C and therefore the sample cannot be 
assigned a percentage predicted loss due to the difficulty in reconstituting the material. It is not 
possible to obtain reliable predictions from the data for +4ºC and +20ºC alone, as insufficient 
degradation has occurred which shows the candidate is stable at +20ºC for up to 1 year.  From 
these data, 15/262 appears to be adequately stable to serve as an IS, and is suitable for ambient 
transportation up to +37ºC as the loss is 0.5% after 1 week (Table 14). Due to its limited batch 
size, the candidate IRP members were not submitted to accelerated degradation assessment. 
Discussion 
The candidate 1
st
 IS for anti-EBOV (sample code 92) is a batch of ampoules containing the 
freeze-dried equivalent of 0.5 mL pooled convalescent plasma obtained from six Sierra 
Leone patients recovered from EVD.  
The candidate 1
st
 IRP of anti-EBOV convalescent plasmas consists of freeze-dried 
preparations of single donations of convalescent plasma obtained from four recovered 
patients and one negative plasma from healthy blood donor. Each panel member is an 
ampoule containing the equivalent of 0.25mL plasma.  
All convalescent plasmas are confirmed PCR-negative for EBOV and, as well as with the 
negative plasma, were SD-treated prior to their development into candidate WHO biological 
reference materials.  
 
Seventeen laboratories from 4 countries participated in this WHO international collaborative 
study to assess the suitability of the candidate materials for use in the standardization of anti-
EBOV assays. Data sets were returned for 26 assay methods (Table 2). Fifteen assay methods 
returned the expected reactivities for the plasma samples, reporting no false negatives or false 
positives (Table 4). This includes the live virus Neut assay (method 16a) that was used as the 
reference method in the previous collaborative study [8], its complementary whole 
inactivated virus ELISA method (16b) and the VSV-luciferase non-replicating PsN (method 
13). These 3 methods have been used in recent EVD or EBOV vaccine studies [9-17]. Nine 
additional EIA methods (1a, 1c, 1d, 3, 5, 7, 8, 14, 15a), one additional VSV-PsN method 
(10b) one LVV-PsN method (4) and the SPR method (17) also returned the expected results. 
Due to laboratory coding, citations for some of the methods are not available. It is known that 
the methods performed by laboratories 8 and 10a are very similar, using the same reference 
standard and controls and method 15a is a commercial assay kit.  Methods 1a, 1d, 5, 8, 10a, 
13, 15a, 16a and 11 were also used in the previous collaborative study [1]. In that study, these 
methods (which are coded differently), also reported the expected reactivities for the 
convalescent and negative plasma samples. As expected, the convalescent plasma samples 
are reactive against non-vaccine target EBOV antigens (Table 4 and Appendix 4). 
 
As reported previously [1], many of the assays used in this collaborative study reported the 
SD-treated normal human plasma as a clear negative while some laboratories reported the 
negative plasma (sample 39 in this study) as positive (Table 4). These are 3 LVV-based PsN 
assays (2, 9, 11) and an in-house ELISA using commercial antigens (6a, 6b, 6c). While these 
results indicate that sample 39 should not be used for determining assay cut-off for the 
respective assays, the material may be useful in the assessment of the non-specific reactivity 
in certain assay methods. 
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Laboratory potency estimates for Neut and PsN are summarized in graphical form for titres 
(Figure 1) and relative potencies against sample 92 (Figure 2).  A graph summarising potency 
estimates relative to sample 92 for EIAs is shown in Figure 3. Graphical summaries for Neut, 
PsN and EIA, overall, are provided of GM potencies relative to sample 92 (Figure 4) and 
sample 15/220 (Figure 5)  
 
The candidate 1
st
 IS for anti-EBOV (SL plasma pool) has a higher potency than the ARC 
plasma sample preparations (15/220 and sample 95). The potencies of the NOR, NHSBT and 
INMI convalescent samples are thought to be near the detection limit of some assays (e.g. 
methods 1b, 12,15b) (See Table 4 and participants’ comments) and cannot be clearly ranked 
across laboratories against the candidate IS and ARC samples. 
 
According to WHO guidelines, the behavior of an International Standard should resemble as 
closely as possible that of the biological samples in the assay systems used to test them [18, 
19] i.e. it should be commutable. The commutability of a biological reference preparation is 
determined by many factors including methods of reference preparation such as inactivation 
or SD treatment and freeze-drying steps; the clinical setting (e.g. immunotherapy or testing 
for immunity); sample matrix (e.g. plasma, serum, urine); and epitope recognition (e.g. whole 
virus, vaccine antigen, EBOV variant). Aspects of commutability of the EBOV antibody 
samples were addressed in this and the previous study [1] by including convalescent plasma 
samples, vaccinee samples, anti-GP monoclonal antibody preparations and anti-GP human 
IgG preparations from transchromosomal bovines. Of these materials, the convalescent 
plasmas most closely resemble EVD clinical specimens; however, such materials are limited 
and difficult to obtain. As potentially sustainable sources of EBOV Ab, consideration should 
be given to assessing the feasibility of the other study materials to serve as biological 
reference materials for EBOV Ab assays. 
 
This study has demonstrated that the agreement between laboratories for potencies relative to 
the candidate IS represents an improvement compared to the agreement in absolute titres, 
however, there is poor agreement between relative potencies for some assays. Commutability 
is not necessarily an intrinsic property of the reference material and must be assessed in the 
context of the assays used. As considered in the previous report, many variables exist in this 
study making it challenging to assess the effects of the candidates on assay variability. 
Factors to consider include the platform, sample matrix, the presence of complement, diluent, 
target cell, EBOV variant of antigen, cross-reactivity against Ebolavirus strains, assay 
protocol and detection readout method.  
 
The implementation and use of sample 92 as the 1
st
 IS for antibodies to EBOV, along with 
the proposed WHO International Reference Panel and the WHO IRR for EBOV antibodies, 
will facilitate the characterization of the factors that contribute to assay variability and 
standardization of results across assays and laboratories. 
 
The results obtained from accelerated thermal degradation studies at ~ 1 year indicate that the 
candidate 1
st
 IS and, by inference, the candidate 1
st
 IRP are stable and suitable for long-term 
use. 
 
Proposal 
It is proposed that the Sierra Leone Anti-EBOV Convalescent Plasma Pool preparation 
(EBOV Ab Sample Code 92) is established as the 1
st
 WHO International Standard for EBOV 
antibodies for use in the standardization of assays used in the detection and quantitation of 
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EBOV antibodies. The 1
st
 IS for EBOV Ab has been assigned a unitage of 1.5 IU/mL when 
reconstituted in 0.5 mL water. 
 
It is proposed that the panel of freeze-dried plasmas consisting of the ARC (Sample Code 
95), NHSBT (Sample Code 66), NOR (Sample Code 38), INMI (Sample Code 85) Anti-
EBOV Convalescent Plasmas and the negative sample (Sample Code 39) is established as the 
1
st
 WHO International Reference Panel for EBOV antibodiesof anti-EBOV Convalescent 
Plasmas.  It is proposed that ARC sample is assigned a unitage of 1.1 IU/mL when 
reconstituted in 0.25mL water. The NHSBT, NOR and INMI panel members have not been 
assigned a unitage. 
 
It is proposed that the WHO IRR for anti-EBOV (NIBCS code 15/220) as established in 2015 
remains available for use. Approximately 250 tubes (100uL/tube) of the current IRR 15/220 
are available for distribution.  
 
It is intended that the WHO IRR and 1
st
 WHO International Reference Panel are used in the 
assessment of factors that affect assay variability.  
 
The WHO IS and IRP for EBOV antibodies are listed under the following NIBSC product 
codes which may be ordered through the NIBSC on-line catalogue 
(http://www.nibsc.org/products.aspx). The proposed instructions for use are given in 
Appendix 11. 
 
NIBSC 15/262: 1
st
 WHO IS Anti-EBOV Convalescent Plasma Pool, Sierra Leone. 
Approximately 950 ampoules of 15/262 are available for distribution. 
 
NIBSC 16/344: 1
st
 WHO IRP Anti-EBOV Convalescent Plasma. Approximately 90 panels 
are available for distribution. 
 
Comments from participants 
 
There were no disagreements with the suitability of the convalescent plasma samples to serve 
as the WHO 1
st
 International Standard (NIBSC code 15/262) and 1
st
 International Reference 
Panel (NIBSC code 16/344) for antibodies to EBOV. One participant suggested that the 
interim WHO IRR (15/220) be withdrawn or not distributed in order to avoid confusion with 
the newly established WHO references materials. Other suggestions have been incorporated 
in the report. 
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Tables 
Table 1. Collaborative study samples shipped under NIBSC dispatch reference CS570. 
EBOV Ab 
Collaborative 
Study Sample 
Code 
NIBSC 
Product 
Code 
Sample Name and description Preparation 
79*  15/220 WHO 1
st
 IRR for Ebola antibodies 
ARC convalescent plasma 
1unit/mL 
100 μL frozen 
plasma 
38 15/284 Candidate Panel Member 3: NOR 
Anti-EBOV Convalescent Plasma 
0.25 mL plasma 
Freeze-dried 
39 15/288 Candidate panel Member  
Negative Human Plasma (anti-EBOV) 
0.25 mL plasma 
Freeze-dried 
66 15/282 Candidate Panel Member 2: NHSBT 
Anti-EBOV Convalescent Plasma 
0.25 mL plasma 
Freeze-dried 
85 15/286 Candidate Panel Member 4: INMI 
Anti-EBOV Convalescent Plasma 
0.25 mL plasma 
Freeze-dried 
92 15/262 Candidate WHO 1
st
 International 
Standard 
Anti-EBOV Convalescent Plasma Pool 
Sierra Leone 
0.5 mL plasma 
Freeze-dried 
93 NA Mab 1-P6 in buffer# 100 μL Liquid 
94 Not 
Applicable 
Mab 1-2-66-4-C12 in buffer# 100 μL Liquid 
95 15/280 Candidate Panel Member 1: ARC 
Anti-EBOV Convalescent Plasma 
0.25 mL plasma 
Freeze-dried 
Abbreviations: * Sample Code 79 was established as the WHO 1
st
 International Reference 
Reagent for Ebola antibodies (NIBSC 15/220) by ECBS in 2015 [1].  IRR = International 
Reference Reagent; ARC = American Red Cross; NOR = Norway; NHSBT= National Health 
Service Blood and Transplant; INMI = National Institute for Infectious Diseases Lazzaro 
Spallanzani; NA = Not Applicable; MAb = monoclonal antibody. 
# PBS-Ca2+-Mg2+; 5% human serum albumin. 
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Table 2. Laboratory codes and assay methods 
Lab 
Code  
Assay Method Description 
[Reference if provided] 
Assay 
Method 
Category 
Analyte (anti-) unit 
1a Direct ELISA screening EIA EBOV GP IgG +/- based on OD 
cut off 
1b Direct ELISA quantification EIA EBOV GP IgG ELISA units/mL 
1c Competitive ELISA EIA EBOV GP IgG OD 
1d IgG Capture ELISA EIA EBOV GP IgG OD 
2 Neutralization assay with 
pseudotyped lentiviral vector 
particles 
LVV PsN EBOV GP RLU 
3 Direct ELISA 
Whole Virion ELISA Assay 
EIA inactivated wv EBOV OD 
4 Neutralization assay LVV LVV-PsN EBOV/Makona GP RLU 
5 Direct ELISA EIA EBOV/Makona rGP IgG OD, WHO IRR 
units/mL, 
units/mg IgG 
6a Direct ELISA EIA EBOV GP OD 
6b Direct ELISA EIA EBOV NP OD 
6c Direct ELISA EIA SUDV NP OD 
6d Western blot analysis against EBOV GP-1 isoform, EBOV GP-1,2 isoform, EBOV NP, SUDV GP 
and SUDV NP 
7 Direct ELISA EIA EBOV VP40 and NP OD 
8 Indirect ELISA EIA EBOV/GP IgG OD and ELISA 
units/mL 
9 Neutralization assay with LVV LVV-PsN  EBOV/Mak-C05 GP RLU 
10a ELISA EIA EBOV GP IgG 
 
OD and ELISA 
units/mL 
10b Neutralization of Ebola 
pseudotypes 
VSV-PsN  EBOV GP Plaques 
11 Neutralization assay with LVV LVV-PsN EBOV/Mak-C15 
(KJ660346) GP 
RLU 
12 Neutralization of Ebola 
pseudotypes (VSV-luciferase 
replication competent 
rcVSV-
PsN 
EBOV GP Mayinga Fluorescence 
13 Neutralization of Ebola 
pseudotypes (VSV-luciferase non-
replicating) (PsVNA, USAMRIID) 
[10, 15, 17, 20] 
nrVSV-
PsN 
EBOV/Kikwit GP-GFP RLU 
14 Direct ELISA EIA EBOV/Kikwit GP OD and ELISA 
units/mL 
15a Direct ELISA EIA EBOV GP IgG OD and ELISA 
units/mL 
15b Neutralisation of infectious EBOV Neut infectious EBOV/Mak-
C05 
Fluorescence 
16a Neutralisation of infectious EBOV Neut live EBOV/Mayinga CPE  
16b Antibody capture ELISA EIA inactivated wv 
EBOV/Makona 
OD 
17 Surface Plasmon Resonance [9] SPR EBOV GP Resonance 
Units 
Abbreviations: EIA = enzyme immunoassay; Neut = neutralisation assay; PsN = pseudotype 
neutralisation assay; LVV = lentiviral vector; VSV = vesicular stomatitis virus vector;  
wv = whole virus; SUDV = Sudan ebolavirus; GP = glycoprotein; NP = nucleoprotein; rc = 
replication-competent; nr = non-replicating; OD = optical density; RLU =  relative light units; 
CPE = cytopathic effect 
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Table 3. Production summary for the candidate International Standard and International Reference Panel members. 
NIBSC code 15/262 15/280 15/282 
CS Code 92 95 66 
Product name 
Candidate WHO 1
st
 IS 
Anti-EBOV plasma, human 
Candidate Panel Member 1: Candidate Panel Member 2: 
Source material 
Sierra Leone convalescent 
plasma pool 
ARC Anti-EBOV convalescent 
plasma 
NHSBT Anti-EBOV convalescent 
plasma 
Presentation Freeze-dried in 3 ml DIN ampoule 
Appearance Robust cake Robust cake Robust cake 
Filling machine Bausch and Strobel AFV5090 Hamilton Hamilton 
Date of filling 29 January 2016 4 March 2016 4 March 2016 
No. of ampoules filled 1203 204 192 
Mean fill weight (g) 
0.5220 
n=84 
0.2536 
n=10 
0.2548 
n=10 
CV of fill weight (%) 0.6652 0.3543 0.3467 
Freeze dryer Serail CS15 Serail CS15* Serail CS15* 
Date of completion of 
lyophilization 
02 February 2016 4 March 2016 4 March 2016 
Mean dry weight (g) 
0.03718 
n=6 
ND ND 
CV of dry weight (%) 0.2800 NA NA 
Mean residual moisture (%) 
0.1616 
n=12 
ND ND 
CV of residual moisture (%) 8.87 NA NA 
Mean oxygen content (%) 
0.31 
n=12 
0.29 
n=12 
0.41 
n=12 
CV of oxygen content (%) 24.42 43.28 26.19 
No. of ampoules 
available to WHO after quality 
control and collaborative study 
~1000 ~100 ~100 
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Table 3. Continued. 
NIBSC code 15/284 15/286 15/288 
CS code 38 85 39 
Product name Candidate Panel Member 3: Candidate Panel Member 4: Candidate Panel Member 
Source material 
NOR Anti-EBOV Convalescent 
Plasma 
INMI Anti-EBOV 
Convalescent Plasma 
Negative Human Plasma 
(anti-EBOV) 
Presentation Freeze-dried in 3 ml DIN ampoule 
Appearance Robust cake Robust cake Robust cake 
Filling machine Hamilton Hamilton Hamilton 
Date of filling 18 March 2016 4 March 2016 18 March 2016 
No. of ampoules filled 218 194 364 
Mean fill weight (g) 
0.2533 
n=10 
0.2552 
n=10 
0.2534 
n=10 
CV of fill weight (%) 0.3 0.222 1.1 
Freeze dryer Serail CS100# Serail CS15* Serail CS100# 
Date of completion of 
lyophilization 
22 March 2016 4 March 2016 22 March 2016 
Mean dry weight (g) ND ND 
0.01762 
n=6 
CV of dry weight (%) NA NA 3.36 
Mean residual moisture (%) ND ND 
0.363 
n=12 
CV of residual moisture (%) NA NA 22.43 
Mean oxygen content (%) 
0.12 
n=12 
0.31 
n=12 
0.26 
n=12 
CV of oxygen content (%) 75.84 25.73 49.06 
No. of ampoules 
available to WHO after quality 
control and collaborative study 
~100 ~100 ~250 
Abbreviations: ARC = American Red Cross; NHSBT= National Health Service Blood and Transplant; NOR = Norway; INMI = National 
Institute for Infectious Diseases Lazzaro Spallanzani; ND= Not Done; NA= Not Applicable. 
* Products 15/280, 15/282 and 15/286 were loaded into the same freeze-dryer for lyophilisation. 
# Products 15/284 and 15/288 were loaded into the same freeze-dryer for lyophilisation. 
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 Table 4. Samples scored as positive or negative for EBOV Ab. 
 
Sample 
CS code 
15/220 
38 39 66 85 92 93 94 95 
NIBSC 15/284 15/288 15/282 15/286 15/262 NA NA 15/280 
Lab Method n 
Analyte 
anti- 
Virus 
1st WHO 
IRR 
(ARC CP) 
NOR CP 
Negative 
plasma 
UK 
NHSBT 
CP 
INMI CP 
Candidate 
WHO 1st IS 
Anti-EBOV 
SL CP 
Mab 1-P6  
Mab 
1-2-66-4-C12 
ARC CP 
1a EIA (screening at 
¼ dilution) 
3 
GP IgG EBOV 
PPP PPP NNN PPP PPP PPP PPP PPP PPP 
1b EIA (quantitation 
at 1/50 dilution) 
3 
GP IgG EBOV 
PPP ND* ND PPP ND* PPP PPP ND* PPP 
1c EIA (competitive, 
tested neat) 
3 
GP IgG EBOV 
PPP PPP NNN PPP PPP PPP NNN NNN PPP 
1d EIA (IgG capture) 3 GP IgG EBOV PPP PPP NNN PPP PPP PPP PPP PPP PPP 
2 LVV-PsN 3** GP EBOV P P p P P P N N P 
3 EIA 
3 
inactivated 
WV 
EBOV 
PPP PPP NNN PPP PPP PPP NNN NNN PPP 
4 LVV-PsN 3 GP Makona PPP PPP NNN PPP PPP PPP PPP PPP PPP 
5 EIA 3 GP Makona PPP PPP NNN PPP PPP PPP PPP PPP PPP 
6a EIA 3 GP EBOV PPP PPP PpI*** PPP PPP PPP PPP PPP PPP 
6b EIA 3 NP EBOV PPP PPP ppN*** PPP PPP PPP NNN NNN PPP 
6c EIA 3 NP SUDV PPP PPP NNp*** PPP PPP PPP NNN NNN PPP 
6d Western  See Appendix 4 
7 EIA 3 VP40 & NP EBOV PPP PPP NNN PPP PPP PPP NNN NNN PPP 
8 EIA 3 GP IgG EBOV PPP PPP NNN PPP PPP PPP PPP PPP PPP 
9 LVV PsN 3 GP Makona PPP PPP ppp PPP PPP PPP PPP NNN PPP 
10a EIA 4 GP IgG EBOV PPPP PPPP NpNN PPPP PPPP PPPP PPPP pPPP PPPP 
10b VSV PsN 4 GP EBOV PPPP PPPP NNNN PPPP PPPP PPPP P,NR,NR,P NR,P,N, NR PPPP 
11 LVV PsN 
3 
EBOV GP Makona 
C15 
PPP pPp ppN PPP PPP PPP PPP PPP P,NI,P 
12 rcVSV PsN 3 GP EBOV PPP I I I# NNN I I I# I I I# PPP PPP PPP PPP 
13 nrVSV PsN 3 GP Kikwit PPP PPP NNN PPP PPP PPP PPP PPP PPP 
14 EIA 3 GP Kikwit PPP PPP NNN PPP PPP PPP PPP PPP PPP 
15a EIA 3 GP IgG EBOV PPP PPP NNN PPP PPP PPP PPP NNN PPP 
15b Neut 3 WV Makona PPP NNN## NNN PpN## ppN## PPP PPP pNN PPP 
16a Neut 3 WV Mayinga PPP PPP NNN PPP PPP PPP PPP PPP PPP 
16b EIA 3 WV Makona PPP PPP NNN PPP PPP PPP PPP NNN PPP 
17 SPR 2 GP EBOV PP PP NN PP PP PP PP NN PP 
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Table 4. continued 
Abbreviations: EIA = enzyme immunoassay; Neut = neutralisation assay; PsN = pseudotype neutralisation assay; LVV = lentiviral vector; VSV = 
vesicular stomatitis virus vector; rc = replication competent; nr = non-replicative; SPR = surface plasmon resonance; GP = glycoprotein; WV = whole 
virus; NP = nucleoprotein; VP40 = matrix protein; EBOV = variant not indicated; SUDV = Sudan virus; ARC = American Red Cross; 
CP = convalescent plasma; NOR = Norway; NHSBT= National Health Service Blood and Transplant; INMI = National Institute for Infectious 
Diseases Lazzaro Spallanzani; SL = Sierra Leone ; NA= not applicable; Mab = monoclonal antibody; N= negative, P= positive; p = weakly positive; 
I= indeterminate; ND = not detected; NI = non-interpretable; NR = not reportable;. 
*Laboratory 1 stated that samples (38, 85 and 94), which scored reactive in the screening assay (1a), have a titre too low to be detected by the 
quantitation assay (1b). 
** Laboratory 2 reported overall reactivity for the 3 assays. 
***Laboratory 6 returned an overall result of negative for sample 39. 
# Laboratory 12 reported samples 38, 66, and 85 as negative/marginally positive. 
## Laboratory 15 reported that the ELISA (15a) was more sensitive than the fluorescence reduction neutralization assay (FRNA) (15b) in identifying 
anti-Ebola antibodies in the provided samples. ELISAs identify total anti-Ebola IgG antibodies whereas the FRNA only identifies neutralizing 
antibodies in a sample, a smaller fraction of the total antibodies produced, which most likely explains the difference in antibody detection between 
these assays. 
Results highlighted in grey are inconsistent with the anticipated reactivity. 
The MAb sample results in BOLD are expected to be negative in anti-NP and anti-VP40 EIA. 
Results highlighted in pink indicate the methods by which one MAb sample is reported positive and the other negative. 
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Table 5. Individual and median titre estimates for neutralisation assays (Neut), lentiviral vector (LVV), pseudoneutralisation (PsN) assays and 
vesicular stomatitis virus vector (VSV) PsN, with potencies expressed relative to samples 15/220 and 92. Unless stated otherwise, the titres are 50% 
reduction neutralisation titres (RNT50). 
Method Lab 
Analyte 
anti- 
Virus Sample 
Log Median Titre 
Median 
Estimate 
Titre 
Relative to 
sample 15/220 
(WHO IRR- 
ARC CP) 
Relative to 
sample 92 
(Candidate 1st 
IS- SL CP) 
Assay 1 Assay 2 Assay 3 
Neut 15b 
Whole 
virus 
Makona isolate C05 
15/220 2.20 2.20 1.90 160 1.00 2.00 
38 no neutralization (no neut.) NA NA NA 
39 no neut. NA NA NA 
66 1.60 1.30 no neut. 28 0.18 0.35 
85 1.30 1.30 no neut. 20 0.13 0.25 
92 1.90 1.90 1.60 80 0.50 1.00 
93 2.20 2.51 2.20 160 1.00 2.00 
94 1.30 no neut. NA NA NA 
95 1.90 2.20 1.60 80 0.50 1.00 
Lab 15 comments: the starting sample dilution was 1/20.  C05 isolate of Ebola Makona (full designation: Ebola virus/H.sapiens-wt/GIN/2014/Makona-C05, abbreviated name: 
EBOV/Mak-C05, GenBank accession no. KP096420.1) was kindly provided by Dr. Gary P. Kobinger (Public Health Agency of Canada). 
The samples were not heat inactivated prior to use. 
All nine samples were tested by ELISA and FRNA (see Appendix 7). The FRNA assay, which detects neutralizing antibodies rather than all Ebola GP specific antibodies, 
measured differing results based on criteria used (50 or 80% reduction). A FRNA50 measured four positive samples, three indeterminate samples, and two negative samples. 
When the neutralization criteria was more stringent (80%), four samples were FNRA positive and five were negative. A total of seven samples were positive for antibodies by 
ELISA and two samples were negative. 
During sample dilution, it was noted that the reconstituted samples were viscous after incubation. 
Neut* 16a 
Whole 
virus 
Mayinga 
15/220 2.48 2.26 2.56 304 1.00 0.60 
38 1.43 1.43 1.28 27 0.09 0.05 
39 0.60 0.83 0.60 4 0.01 0.01 
66 1.81 1.96 1.51 64 0.21 0.13 
85 1.43 1.35 1.51 27 0.09 0.05 
92 2.71 2.71 2.18 512 1.68 1.00 
93 3.01 3.01 3.16 1024 3.36 2.00 
94 2.03 3.01 1.81 108 0.35 0.21 
95 2.41 2.78 2.18 256 0.84 0.50 
*100% neutralisation titres reported.  
Lab 16 comments: All samples were evaluated by ELISA using inactivated Ebola Zaire Makona virus and virus neutralization assay using live Ebola Zaire Mayinga virus. All 
samples were tested in three independent experiments in both assays. With the exception for sample 94, ELISA and NT data correlated well with each other. For sample 94 we 
conclude that these antibodies most likely recognize conformation-dependent epitopes that are sensitive to SDS and heat treatment (see Appendix 8). 
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Table 5 continued 
Method Lab Analyte anti- Virus Sample 
Log Median Titre 
Median 
Estimate 
Relative to 
sample 15/220 
(WHO IRR- 
ARC CP) 
Relative to 
sample 92 
(Candidate 1st 
IS- SL CP) 
Assay 1 Assay 2 Assay 3 
LVV-PsN 2 GP EBOV 
15/220* 2.47 2.95 2.79 610 1.00 1.40 
38* 2.34 2.65 2.54 349 0.57 0.80 
39* 1.73 1.78 1.79 61 0.10 0.14 
66* 2.22 2.51 2.25 178 0.29 0.41 
85 2.12 2.53 2.34 217 0.36 0.50 
92* 2.16 2.64 2.72 436 0.72 1.00 
93 1.77 1.35 1.87 58 0.10 0.13 
94 0.71 no neut. 1.17 9 0.01 0.02 
95* 2.37 2.46 2.50 290 0.48 0.67 
Lab 2 comments: Some pipetting problems due to viscosity of some samples. *Concentration-dependent inhibition was noted for these samples. 
LVV-PsN 4 Gp Makona 
15/220 2.25 2.27 2.57 187 1.00 0.51 
38 NA* 1.77 2.00 76 0.41 0.21 
39 No neutralization shown NA NA NA 
66 1.81 1.90 1.77 65 0.35 0.18 
85 2.09 1.89 2.19 123 0.66 0.34 
92 2.68 2.56 2.52 365 1.95 1.00 
93 2.95 2.77 2.80 627 3.35 1.72 
94 3.45 3.49 3.74 3117 16.67 8.54 
95 2.32 2.52 2.49 311 1.66 0.85 
NA = Not assessed. Lab 4 comments: * Although we couldn’t produce a titration curve, on the single point analysis 2 out of 3 replicates neutralise 50% at dilution 1/20. 
LVV-PsN 9 GP Makona 
15/220 2.34 2.69 2.27 220 1.00 NA 
38 1.81 1.80 1.65 63 0.28 NA 
39 1.69 1.40 1.43 27 0.12 NA 
66 2.19 2.28 2.08 153 0.70 NA 
85 2.03 2.15 1.97 108 0.49 NA 
Assays were split across 2 plates 
92 2.43 2.24 2.27 186 NA 1.00 
93 2.83 2.84 2.69 683 NA 3.67 
94 <1.60 1.36 <1.60 NA NA NA 
95 2.32 2.16 2.23 171 NA 0.92 
NA = Not assessed. Lab 9 comments: We heat-inactivate antibodies at 56°C x 30 minutes prior to use and do not use complement in our assay. Based on use of negative sera in 
our prior experiments, we expect that titers < 40 (i.e. Log 1.60) are negative. 
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Table 5 continued 
Method Lab Analyte anti- Virus Sample 
Log Median Titre 
Median 
Estimate 
Relative to 
sample 
15/220 
(WHO IRR- 
ARC CP) 
Relative to 
sample 92 
(Candidate 1st 
IS- SL CP) Assay 1 Assay 2 Assay 3 
LVV-
PsN 
11 GP Makona isolate C15 
15/220 2.35 2.35 2.20 226 1.00 0.25 
38* 1.30 1.90 1.30 20 0.09 0.02 
39 1.75 1.45 1.30 28 0.12 0.03 
66* 3.71 4.01 3.86 7241 32.00 8.00 
85 2.66 2.35 2.35 226 1.00 0.25 
92 2.81 2.96 3.11 905 4.00 1.00 
93 2.51 3.11 2.51 320 1.41 0.35 
94 3.56 4.16 3.56 3620 16.00 4.00 
95* 3.11 uninterpretable 2.35 NA NA NA 
NA = not assessed. Lab 11 comments: * Samples 38, 66 and 95 produced dilution curves that were difficult to interpret.  
Method Lab 
Analyte 
anti- 
Virus Sample 
Log Median Titre 
Median 
Estimate 
Relative to 
sample 
15/220 
(WHO IRR- 
ARC CP) 
Relative to 
sample 92 
(Candidate 1st 
IS- SL CP) 
Assay 1 Assay 2 Assay 3 Assay 4 
VSV-
PsN 
10b* GP EBOV 
15/220 3.72 3.91 3.61 NR 5230 1.00 0.90 
38 3.18 3.20 3.07 3.03 1331 0.26 0.23 
39 <1.30 <1.30 <1.30 <1.30 NA NA NA 
66 3.23 3.19 3.23 3.17 1619 0.31 0.28 
85 3.12 3.06 3.03 2.89 1101 0.21 0.19 
92 3.72 3.84 3.81 3.72 5845 1.12 1.00 
93 3.82 NR NR 3.26 NA NA NA 
94 NR 2.84 <1.30 NR NA NA NA 
95 3.61 3.78 3.57 3.59 3953 0.76 0.68 
* PRNT60 titres reported. NA = not assessed; NR= not reportable. 
Lab 10 comments: Additional participant’s comments about results obtained with their ELISA and PRNT are given in Appendix 5. 
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Table 5 continued 
Method Lab 
Analyte 
anti- 
Virus Sample 
Log Median Titre 
Median 
Estimate 
Relative to 
sample 
15/220 
(WHO IRR- 
ARC CP) 
Relative to 
sample 92 
(Candidate 1st 
IS- SL CP) 
Assay 1 Assay 2 Assay 3 
rcVSV-
PsN 
12 GP EBOV 
15/220 2.63 2.60 2.77 426 1.00 2.15 
38 * * * NA NA NA 
39 negative negative negative NA NA NA 
66 * * * NA NA NA 
85 * * * NA NA NA 
92 2.47 2.27 2.30 198 0.46 1.00 
93 2.29 2.02 2.12 131 0.31 0.66 
94 3.31 3.35 3.47 2225 5.22 11.24 
95 2.45 2.41 2.58 279 0.65 1.41 
NA = not assessed 
Lab 12 comments: *Samples 38, 66, 85 are negative or marginally positive (equivocal). FRNT50 cannot be determined.  
nrVSV-
PsN 
13 GP Kikwit 
15/220 3.30 3.27 3.37 1978 1.00 0.77 
38 2.38 2.38 2.51 240 0.12 0.09 
39 < < < NA NA NA 
66 2.71 2.89 3.05 782 0.40 0.30 
85 2.45 2.57 2.99 371 0.19 0.14 
92 3.22 3.41 3.76 2572 1.30 1.00 
93 3.88 3.98 4.36 9632 4.87 3.74 
94 4.67 4.48 4.87 46513 23.51 18.09 
95 3.03 3.27 3.39 1843 0.93 0.72 
Lab 13 comments Additional participant’s comments about the PRNT50 and PRNT80 results are given in Appendix 6. 
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Table 6. Summary of median neutralizing antibody titres for convalescent plasmas tested in neutralisation (Neut), lentiviral vector (LVV) 
pseudoneutralisation (PsN) and vesicular stomatitis virus vector (VSV) PsN assays. Also shown are overall geometric mean titres and geometric 
coefficients of variation. Unless stated otherwise, the titres are 50% reduction neutralisation titres (RNT50). 
 
Neutralisation Method 
Lab 
code 
Median Neut/PsN titres 
RNT50 unless stated otherwise Comments 
15/220 38 66 85 92 95 
Neut, Whole virus 
Makona isolate C05 
15b 160 n/a 28 20 80 80  
Neut, Whole virus, Mayinga 16a 304 27 64 27 512 256 100% neutralisation titre 
LVV-PsN, EBOV 2 610 349 178 217 436 290  
LVV-PsN, Makona 4 187 76 65 123 365 311  
LVV-PsN, Makona 9 220 63 153 108 186 171  
LVV-PsN, Makona isolate C15 11 226 20# 7241# 226 905 n/a#  
VSV-PsN, EBOV 10b 5230 1331 1619 1101 5845 3953 RNT60 
rcVSV-PsN, EBOV 12 426 n/a n/a n/a 198 279  
nrVSV-PsN, EBOV 13 1978 240 782 371 2572 1843  
 
Overall GM 474 116 271 139 529 399  
Overall GCV 228% 348% 558% 275% 282% 258%  
Except samples 38 and 66 
for laboratory 11 
Overall GM 
 
156 170 
 
 
 
 
Overall GCV 308% 324%  
Abbreviations: GM = Geometric mean; GCV = geometric coefficient of variation.  
n/a = Median titre not assessed. 
# Titration curves were difficult to interpret for these samples. 
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Table 7. Summary of individual laboratory median potencies expressed relative to the candidate 1
st
 IS for EBOV Ab (Sample 92) for convalescent 
plasma samples tested in neutralisation (Neut), lentiviral vector (LVV) pseudoneutralisation (PsN) and vesicular stomatitis virus vector (VSV) PsN 
assays. Also shown are overall geometric mean potencies and geometric coefficients of variation. 
 
Neutralisation Method 
Lab 
code 
Potencies relative to sample 92 
15/220 38 66 85 92 95 
Neut, Whole virus 
Makona isolate C05 
15b 2.00 n/a 0.35 0.25 1.00 1.00 
Neut, Whole virus, Mayinga 16a 0.59 0.05 0.13 0.05 1.00 0.50 
LVV-PsN, EBOV 2 1.40 0.80 0.41 0.50 1.00 0.67 
LVV-PsN, Makona 4 0.51 0.21 0.18 0.34 1.00 0.85 
LVV-PsN, Makona 9* n/a n/a n/a n/a 1.00 0.92 
LVV-PsN, Makona isolate C15 11 0.25 0.02# 8.00# 0.25 1.00 n/a# 
VSV-PsN, EBOV 10b 0.89 0.23 0.28 0.19 1.00 0.68 
rcVSV-PsN, EBOV 12 2.15 n/a n/a n/a 1.00 1.41 
nrVSV-PsN, EBOV 13 0.77 0.09 0.30 0.14 1.00 0.72 
 Overall GM 0.87 0.13 0.42 0.20 1.00 0.81 
Overall GCV 108% 251% 292% 105% 0% 37% 
Except samples 38 and 66 
for laboratory 11 
Overall GM  0.18 0.25    
Overall GCV 180% 56% 
Abbreviations: GM = Geometric mean; GCV = geometric coefficient of variation. 
* Samples not included on the same plate as sample 92 were not assessed. 
n/a = Relative potency not assessed;. 
# Titration curves were difficult to interpret for this sample. 
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Table 8. Summary of individual laboratory median potencies expressed relative to the current WHO IRR for EBOV Ab (Sample 15/220) for 
convalescent plasma samples tested in neutralisation (Neut), lentiviral vector (LVV) pseudoneutralisation (PsN) and vesicular stomatitis virus vector 
(VSV) PsN assays. Also shown are overall geometric mean potencies and geometric coefficients of variation.  
 
Neutralisation Method Lab 
code 
Potencies relative to sample 15/220 
15/220 38 66 85 92 95 
Neut, Whole virus, 
Makona isolate C05 
15b 1.00 n/a 0.18 0.13 0.50 0.50 
Neut, Whole virus, Mayinga 16a 1.00 0.09 0.21 0.09 1.68 0.84 
LVV-PsN, EBOV 2 1.00 0.57 0.29 0.36 0.72 0.48 
LVV-PsN, Makona 4 1.00 0.41 0.35 0.66 1.95 1.66 
LVV-PsN, Makona 9* 1.00 0.29 0.70 0.49 n/a n/a 
LVV-PsN, Makona isolate C15 11 1.00 0.09 32.00 1.00 4.00 n/a 
VSV-PsN, EBOV 10b 1.00 0.25 0.31 0.21 1.12 0.76 
rcVSV-PsN, EBOV 12 1.00 n/a n/a n/a 0.46 0.65 
nrVSV-PsN, EBOV 13 1.00 0.12 0.40 0.19 1.30 0.93 
 Overall GM 1.00 0.21 0.56 0.29 1.16 0.77 
Overall GCV 0% 111% 438% 131% 108% 53% 
Except samples 38 and 66 
for laboratory 11 
Overall GM  0.24 0.32    
Overall GCV 104% 56% 
Abbreviations: GM = Geometric mean; GCV = geometric coefficient of variation.  
*Samples not included on the same plate as sample 15/220 were not assessed. 
n/a = Relative potency not assessed. 
# Titration curves were difficult to interpret for these samples. 
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Table 9. Individual ELISA potency estimates relative to sample 92. 
 
Lab Assay 15/220 38 66 85 93 94 95 
1a, 1b, 1c, 1d Not amenable to parallel line analysis 
3 
1 0.136 0.243 Non-parallel Invalid* ND ND Non-parallel 
2 0.795 1.505 5.403 Non-linear ND ND Non-parallel 
3 0.379 0.927 Non-parallel Non-parallel ND ND Non-parallel 
5 
1 1.119 
Not assessed** Not assessed** 
0.256 
Not assessed** Not assessed** 
1.075 
2 1.402 0.265 1.110 
3 1.219 0.273 1.118 
6a 
1 0.581 0.392 0.255 0.210 4.746 OOR 0.484 
2 0.508 0.241 0.218 0.219 Non-parallel OOR 0.421 
3 0.910 0.383 0.352 0.296 6.685 OOR 0.409 
6b 
1 Non-parallel 0.464 0.185 0.493 ND ND OOR 
2 Non-parallel Non-parallel Non-parallel Non-parallel ND ND OOR 
3 0.257 0.630 Non-parallel 0.658 ND ND OOR 
7 
1 0.689 0.499 0.626 1.447 OOR OOR 0.542 
2 0.651 0.233 0.524 1.222 OOR OOR Non-parallel 
3 0.571 0.377 0.418 1.053 OOR OOR 0.659 
8 
1 0.267 0.291 0.201 0.315 7.053 0.040 0.888 
2 Non-linear 0.310 0.408 Non-parallel Non-parallel 0.053 0.810 
3 0.153 0.224 Non-parallel 0.367 Non-linear 0.032 1.555 
10 
1 0.962 0.469 0.320 0.329 Non-parallel OOR 0.856 
2 1.381 0.709 0.309 0.448 Non-parallel 0.052 1.090 
3 0.979 0.570 0.347 0.330 5.581 0.042 0.850 
4 Non-linear Invalid# Invalid# Invalid# Invalid# Invalid# Invalid# 
14 
1 0.417 0.460 0.199 0.412 Non-parallel 0.041 0.668 
2 0.761 0.662 0.296 0.489 Non-parallel 0.053 0.924 
3 Non-parallel 0.396 0.217 0.352 Non-parallel 0.060 0.640 
15 
1 
Not assessed** Not assessed** Not assessed** Not assessed** 
1.206 OOR 0.402 
2 1.236 OOR 0.387 
3 1.236 OOR 0.387 
16b Reported at 1/200 dilution. Not amenable to parallel line analysis. 
OOR = out of range-high. Sample not assessed 
* Invalid due to variability between replicates; ** Samples not included on the same plate as sample 92 were not assessed. # Non-linear reference sample. 
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Table 10. ELISA results summary. Geometric mean potencies expressed relative to sample 92 
 
Sample 15/220 38 66 85 93 94 95 
Lab 
Code 
Analyte 
anti- 
Virus N GM GCV N GM GCV N GM GCV N GM GCV N GM GCV N GM GCV N GM GCV 
3 inactivated WV EBOV 3 0.345 143% 3 0.697 157% 1 5.403* NA 0 IV NA  ND NA  ND NA 0 IV NA 
5** GP IgG Makona 3 1.241 12% 3 NA NA 3 NA NA 3 0.265 3% 0 NA NA 0 NA NA 3 1.101 2% 
6a GP EBOV 3 0.645 36% 3 0.331 31% 3 0.270 28% 3 0.239 21% 2 5.633 NA 0 OOR NA 3 0.437 9% 
6b NP EBOV 1 0.257 NA 2 0.540 NA 1 0.185 NA 2 0.569 NA 0 NA NA 0 NA NA 0 OOR NA 
7 VP40 & NP EBOV 3 0.635 10% 3 0.353 47% 3 0.516 23% 3 1.230 17%  ND NA  ND NA 2 0.598 NA 
8 GP IgG EBOV 2 0.202 NA 3 0.272 19% 2 0.287 NA 2 0.340 NA 1 7.053 NA 3 0.041 28% 3 1.038 42% 
10 GP IgG EBOV 3 1.091 23% 3 0.575 23% 3 0.325 6% 3 0.365 19% 1 5.581 NA 2 0.047 NA 3 0.926 15% 
14 GP Kikwit 2 0.563 NA 3 0.494 30% 3 0.234 23% 3 0.414 18% 0 IV NA 3 0.051 21% 3 0.734 22% 
15a** GP IgG EBOV 0 NA NA 0 NA NA 0 NA NA 0 NA NA 3 1.117 1%  ND NA 3 0.392 2% 
Overall GM 0.52 0.44 0.29 0.42 4.06 0.05 0.70 
Overall GCV 92% 41% 41% 74% 124% 12% 51% 
Overall GM excluding labs 6b and 7 0.57 0.48 0.28 0.32 4.06 0.05 0.72 
Overall GCV excluding labs 6b and 7 99% 48% 15% 26% 124% 12% 53% 
Abbreviations: GM = Geometric mean; GCV = geometric coefficient of variation; WV = whole virus; GP = glycoprotein; NP = nucleoprotein; VP40 = 
matrix protein ; IV = all assays invalid for this sample; NA= not assessed; ND= not detected; OOR = out of range-high;  
* The discrepant value from a single assay was not included in calculation of overall GM and overall %GCV. 
** Samples not included on the same plate as sample 92 were not assessed. 
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Table 11. ELISA results summary. Geometric mean potencies expressed relative to sample 15/220. 
 
Sample GM 
Lab Code 
Analyte 
anti- 
Virus 92 38 66 85 93 94 95 
3 
inactivated 
WV 
EBOV 2.901 2.022 15.674*  ND ND  
5** GP IgG Makona 0.806   0.213   0.887 
6a GP EBOV 1.550 0.513 0.418 0.370 8.731  0.678 
6b NP EBOV 3.893 2.103 0.720 2.217    
7 VP40 & NP EBOV 1.574 0.555 0.812 1.937   0.941 
8 GP IgG EBOV 4.949 1.348 1.419 1.683 34.904* 0.201 5.136 
10 GP IgG EBOV 0.916 0.527 0.298 0.334 5.114 0.043 0.848 
14 GP Kikwit 1.776 0.877 0.416 0.735  0.090 1.303 
15a** GP IgG EBOV        
Overall GM 1.91 0.96 0.59 0.76 6.68 0.09 1.22 
Overall GCV 92% 87% 77% 160% 46% 117% 109% 
Overall GM excluding labs 6b and 7 1.76 0.92 0.52 0.50   1.28 
Overall GCV excluding labs 6b and 7 99% 81% 99% 124%   125% 
Abbreviations: GM = Geometric mean; GCV = geometric coefficient of variation; WV = whole virus; GP = glycoprotein; NP = nucleoprotein; VP40 = 
matrix protein ; IV = all assays invalid for this sample; NA= not assessed; ND= not detected; OOR = out of range-high;  
* The discrepant value from a single assay was not included in the calculation of overall GM and overall %GCV. 
** Samples not included on the same plate as sample 92 were not assessed. 
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Table 12. Surface Plasmon Resonance results summary. Potencies expressed relative to samples 92 and 15/220. See appendix 9 for the SPR raw data. 
 
Relative to Sample 92 
Sample 92 15/220 38 66 85 93 94 95 
Assay 1 1.000 0.756 Non-linear 0.244 0.490 0.221 ND 0.425 
Assay 2 1.000 0.755 Non-linear 0.243 0.490 0.222 ND 0.443 
Mean 1.00 0.76 NA 0.24 0.49 0.22 NA 0.43 
Relative to Sample 15/220 
Sample 92 15/220 38 66 85 93 94 95 
Assay 1 1.322 1.000 
Non-linear 
0.322 0.648 0.292 ND 0.562 
Assay 2 1.324 1.000 
Non-linear 
0.322 0.649 0.294 ND 0.587 
Mean 1.32 1.00 NA 0.32 0.65 0.29 NA 0.57 
 
NA = relative potency not assessed 
ND = Not detected 
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Table 13. Overall geometric mean potencies across all assays expressed relative to the candidate 
IS (sample 92) and IRR (15/220). 
 
lower 95% confidence limit 0.57 0.24 0.24 0.25  0.66 
Overall GM relative to 92 0.68 0.30 0.27 0.30 1.00 0.73 
upper 95% confidence limit 0.80 0.38 0.30 0.36  0.80 
Overall GCV 100% 130% 44% 105%  45% 
lower 95% confidence limit  0.35 0.36 0.37 1.25 0.98 
Overall GM relative to 
15/220 
1.00 0.45 0.40 0.45 1.47 1.07 
upper 95% confidence limit  0.57 0.44 0.54 1.75 1.18 
Abbreviations: GM = Geometric mean; GCV = geometric coefficient of variation 
 
 
 
 
 
Table 14. Predicted degradation rates for candidate WHO 1
st
 IS for EBOV Ab 15/262. 
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Figure 1. Median titre estimates for neutralisation assays (Neut) and pseudo-neutralisation (PsN) 
assays. 
 
Notes: * Discrepant value from a single assay was not included in graph; # Positive- relative 
potency not determined; ** Relative potency was not determined for samples not included on the 
same plate as sample 92. 
  
WHO/BS/2017.2316 
Page 36 
 
Figure 2. Laboratory potencies relative to sample 92 for neutralisation assays (Neut) and 
pseudoneutralisation (PsN) assays. 
 
 
Notes: * Discrepant value from a single assay was not included in graph; # Positive- relative 
potency not determined; ** Relative potency was not determined for samples not included on the 
same plate as sample 92. 
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Figure 3. Laboratory potencies relative to sample 92 for enzyme immunoassays and SPR. 
 
Notes: * Discrepant value from a single assay was not included in graph; # Positive- relative 
potency not determined; ** Relative potency was not determined for samples not included on the 
same plate as sample 92. 
  
WHO/BS/2017.2316 
Page 38 
 
Figure 4 
 
 
Figure 5 
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Appendix 1 
Collaborative study participants  
(In alphabetical order by country) 
Name Laboratory Country 
Béatrice Labrosse, Christophe 
Léculier, Delphine Pannetier 
Laboratoire P4 Inserm Jean Mérieux France 
Thomas Strecker, Verena 
Krähling, Sarah Katharina 
Fehling 
Institute of Virology of the Philipps-
University, Marburg 
Germany 
Barbara Schnierle, Lisa Henss Paul-Ehrlich-Institut Germany 
Derek Gatherer, Lisa Bishop, 
Katharina Hartman, Robert 
Lauder, Marcell Mullner, Hoang 
Son Tran 
Lancaster University UK 
Sophie Myhill, Giada Mattiuzzo NIBSC UK 
Edward Wright, Emma Bentley University of Westminster UK 
Richard Tedder, Dhan Samuel, 
Steve Dicks 
Virus Reference Department, Public 
Health England, Colindale 
UK 
Thomas Rudge Battelle-BBRC USA* 
Matthew L. Boisen Zalgen Labs LLC USA 
Anna N Honko, Richard S. 
Bennett, 
Jamie Pettitt, Krisztina Janosko, 
Jonathan Marchand, Elena 
Postnikova,  
Integrated Research Facility, National 
Institutes of Allergy and Infectious 
Diseases 
USA 
Gerardo Kaplan, Krishnamurthy 
Konduru, 
Office of Blood Research and Review, 
CBER-FDA 
USA 
Surender Khurana 
Office of Vaccine Research and 
Review (OVRR), CBER, FDA 
USA 
Carol D. Weiss OVRR, CBER, FDA USA 
Wayne R. Hogrefe, 
Nicole Rodriguez, 
Rohini G. Sandesara, 
Sarah L. Daijogo 
Q2 Focus Diagnostics Clinical Trials. USA 
Hua Wu SAB Biotherapeutics Inc. USA 
Jay W. Hooper, Steve A. Kwilas, 
Meagan Wisniewski 
United States Army Medical Research 
Institute of Infectious Diseases 
(USAMRIID) 
USA 
Peter M. Silvera USAMRIID USA 
 
*Steven A. Rubin, FDA/CBER facilitated sample permits and shipments to laboratories in the 
USA. 
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Appendix 2 
Ebola CP Consortium investigators 
Name Affiliation Country 
MG Semple, (Consortium 
Lead Investigator) 
JT Scott 
Institute of Translational Medicine and NIHR 
Health Protection Research Unit in Emerging 
and Zoonotic Infections University of 
Liverpool, Liverpool 
UK 
SM Gevao (Country Lead 
Investigator) 
F Sahr (Country Deputy Lead 
Investigator) 
CP Cole, J Russell 
College of Medicine and Allied Health 
Sciences, Freetown 
Sierra Leone 
S Baker, O Kargbo, P Kamara 
National Safe Blood Service, Connaught 
Hospital, Ministry of Health & Sanitation, 
Freetown 
Sierra Leone 
M Lado, CS Brown 
King’s Sierra Leone Health Partnership, King’s 
Health Partners & King’s College London, 
London 
UK 
J van Griensven, R Ravinetto,  
Y Claeys 
Institute of Tropical Medicine, Antwerp Belgium 
RS Tedder, R Gopal, 
TJG Brooks 
National Infection Service, Public Health 
England, London 
UK 
CC Smith Health Protection Scotland UK 
HA Doughty 
NHS Blood and Transplant, & College of 
Medical and Dental Sciences, University of 
Birmingham, Birmingham 
UK 
A Mari Saez, M Borchert 
Institute for Tropical Medicine and 
International Health, Charité, Berlin 
Germany 
AH Kelly 
Department of Sociology, Philosophy and 
Anthropology, Exeter University, Exeter 
UK 
JK Baillie 
The Roslin Institute, University of Edinburgh, 
Edinburgh 
UK 
N Shindo, D Pfeifer 
Department of Pandemic and Epidemic 
Diseases, World Health Organization Geneva 
Switzerland 
DL Hoover ClinicalRM Inc., Ohio USA 
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Appendix 3 
Collaborative Study Protocol 
WHO International Collaborative Study to Establish the 
1
st
 International Standard for Ebola Virus Antibodies 
In October 2015, the WHO Expert Committee on Biological Standardization (ECBS) established a 
preparation of plasma (NIBSC product code 15/220) obtained from a patient recovered from Ebola virus 
disease (EVD) to serve as the WHO 1
st
 International Reference Reagent for Ebola antibodies with an 
assigned potency of 1 unit per mL. NIBSC 15/220 was assessed in a WHO international collaborative 
study and is known in that study as EBOV Ab Sample Code 79 [1, 2].  
15/220 is serving as the interim WHO Reference Reagent for EBOV antibodies 
(https://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=15/220) while we 
undertake further work to develop a candidate preparation and evaluate its suitability to serve as the 
WHO 1
st
 International Standard for EBOV antibodies. WHO International Standards are recognized as 
the highest order of reference materials for biological substances and they are assigned potencies in 
International Units (IU).  International Standards are used to quantify the amount of biological activity 
present in a sample in terms of the IU, making assays from different laboratories comparable.  This makes 
it possible to better define parameters such as the analytical sensitivity of tests or clinical parameters such 
as protective levels of antibody [3].  In addition to the 1
st
 International Standard, we are developing a 
WHO Reference Panel of 5 to 7 EBOV antibody samples for testing and comparison across assays and 
laboratories. 
Participation in the study will involve the testing of the candidate International Standard and other 
antibody preparations alongside the WHO International Reference Reagent (15/220) in assay(s) that are in 
routine use in the participant’s laboratory. The aims [3] of this WHO international collaborative study are 
to  
 assess the suitability of the candidate to serve as the International Standard with an assigned 
unitage in IU per vial for use in the harmonization of EBOV antibody assays. There is no 
international conventional reference measurement procedure for EBOV antibodies and the IU is 
not traceable to the International System of Units (SI) of quantity 
 identify additional candidate EBOV antibody preparations for inclusion in a WHO International 
Reference Panel for EBOV antibodies.  
 characterise each candidate preparation in terms of reactivity/specificity.  
 assess each candidate’s potency i.e. readout in a range of typical assays performed in different 
laboratories 
 assess commutability i.e. to establish the extent to which each candidate is suitable to serve as an 
international standard for the variety of different samples and assay types. 
 recommend to WHO ECBS for establishment the candidate found to be suitable to serve as the 1st 
International Standard. 
 recommend to WHO ECBS the establishment of the EBOV antibody reference panel. 
Study Samples 
1. Candidate 1st WHO International Standard for antibodies to EBOV 
The candidate material is a pool of plasmas obtained from six Sierra Leone patients recovered from EVD 
(Provided by Dr Calum Semple, University of Liverpool, UK). The treatment histories of the Sierra 
Leone patients are not known. Approximately 1000 ampoules containing the freeze-dried equivalent of 
0.5mL plasma have been prepared at NIBSC. 
2. Candidate WHO Reference Panel Samples for EBOV antibodies 
The candidate panel members will be evaluated alongside the candidate International Standard. Members 
of the panel may include negative samples, reactive samples from convalescent patients and monoclonal 
antibody formulations. We currently do not have samples from human recipients of Ebola vaccines for 
inclusion in the study.  
 National Institute for Infectious Diseases Lazzaro Spallanzani (INMI) donor (provided by 
Maria Rosaria Capobianchi, INMI, Italy): The INMI patient had received Favipiravir, 3 
treatments of convalescent plasma from 2 donors, ZMAb and Melanocortin (TCS 10). 
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 Norway (NOR) donor (provided by Dr Richard W. Olaussen, Oslo University): The Ebola-
specific therapeutic treatments given to the NOR patient include ZMAb (anti-GP), Favipiravir 
(RNA pol inhibitor) and TKM-100802 (iRNA). 
 American Red Cross (ARC) donor (provided by Dr Susan L. Stramer, ARC): The ARC 
patient received 2 aliquots of convalescent plasma 24 hours apart, as well as 7 nightly infusions 
of TKM-Ebola (iRNA). The ARC donor did not receive monoclonal antibody treatments. 
 UK National Health Service Blood and Transplant (NHSBT) donor (provided by Dr Sheila 
MacLennan, Leeds): The NHSBT patient received Brincidifovar sp.? (anti-viral) and 
convalescent plasma treatments. 
Prior to shipment to the UK, all convalescent plasmas were tested and found negative for EBOV RNA. 
Prior to receipt at NIBSC, the convalescent plasmas were held at Public Health England (PHE), 
Colindale, UK until confirmed by PCR that no EBOV RNA could be detected in the materials. After 
receipt at NIBCS, plasma donations were solvent-detergent extracted as described in the ECBS 
collaborative study report [1]. For each panel member, approximately 200 to 600 ampoules containing the 
freeze-dried plasma have been prepared at NIBSC. 
Please note that, while the NOR, ARC and NHSBT source materials listed above are the same as those 
described in the ECBS report [1], they have been prepared independently for assessment in this 
collaborative. For example, the NOR, ARC and NHSBT samples for this collaborative study have 
undergone separate solvent-detergent treatments with respect to Sample 43,79 and 79 from the previous 
study. Furthermore, the NOR, ARC and NHSBT have been freeze-dried for this collaborative study, 
whereas the corresponding samples in the earlier study were liquid presentations.  
 Purified monoclonal antibodies donated by Prof A. Townsend, University of Oxford, UK: 
These were cloned from B cells of volunteers participating in the Oxford, UK vaccine trial who 
have been primed with the monovalent formulation of the chimpanzee adenovirus 3 (ChAd3)-
vectored vaccine encoding the surface glycoprotein of Ebola virus (GSK/NIH vaccine candidate) 
[4]. 
Two MAbs have been prepared in sterile PBS-Ca2+-Mg2+ supplemented with 5% human serum albumin. 
One-hundred vials of each MAb in 100µL liquid aliquots have been prepared. 
Assay Methods 
For testing the study samples, participants are requested to use the method(s) in routine use in their 
laboratory for the detection of antibodies to Ebola.  Laboratories may use multiple methods to test the 
study materials provided that the study design is followed for each method. 
Design of study 
Participants are requested to: 
 perform 3 independent assays on different days for antibodies against Ebola. Laboratories will 
receive at least 3 sets of study samples which should allow for 3 independent assays by one 
method.  Laboratories with more than one assay method will receive additional sample sets to 
allow 3 independent assays per method (subject to availability). Based on availability, spare 
vials/ampoules of certain samples will be provided to allow participants to run a preliminary 
assay in order to ascertain working dilutions.  
 Reconstitute freeze-dried samples according to the Instructions for Use (IFU) supplied with the 
sample shipment. Use a freshly thawed/reconstituted sample for each independent assay. 
 for each independent assay, prepare and test a series of dilutions from each coded sample. If 
possible at least two independent replicate series of dilutions (NOT two samplings from a single 
series) should be prepared and assayed.    Participants are requested to dilute the samples using 
the sample matrix specific to their individual assay(s) (e.g. plasma, serum, buffer).  The optimal 
dilution range should cover at least 4 steps including one step beyond the endpoint dilution.  
Adjust dilutions accordingly for subsequent assays if needed.  Record in the excel 
spreadsheet changes to the dilutions tested. 
 use the Excel reporting sheet to record for each dilution the assay readout (e.g. from the 
spectrophotometer/luminometer/plaque count etc.).  Our statistician will use the raw data readouts 
to perform the statistical analysis. 
 include the cut-off value indicating sero-reactivity for each assay and whether each sample 
dilution tested is considered positive or negative according to assay criteria. 
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 Include all study samples in each assay so that the potency of antibodies relative to one another 
may be calculated.  Please note in the reporting sheet if it is not practicable to test all samples 
concurrently indicating which samples where tested concurrently. 
 Record in the Excel reporting sheet any deviations from the assay protocol. 
 
Results and data analysis 
Participants are requested to return their results to NIBSC within 6 weeks of receipt of the study 
materials.  If it is not practicable to turn around results within 6 weeks, please inform 
dianna.wilkinson@nibsc.org. An excel spread sheet will be provided so that all essential information can 
be recorded including details of assay methodology and the raw data obtained from each assay.  The use 
of the reporting spread sheet facilitates the analysis and interpretation of results.  If multiple assay 
methods are undertaken, a separate worksheet for each method should be completed.  The reporting 
spread sheet will be e-mailed to each participant closer to the launch of the collaborative study. 
The confidentiality of each laboratory will be ensured with each participant being anonymous to the other 
laboratories.  Analysis of the study will assess the potencies of each material relative to each other, and 
the sensitivity of the different assay methods.   
Assay data will be analysed at NIBSC by an experienced biometrician using standard statistical 
techniques.  
A draft study report will be sent to participants for comment.  The report will include data analysis, 
proposed conclusions and recommendations to the WHO ECBS on the selection, use and unitage of the 
1
st
 International Reference Reagent and Reference Panel for use in assays for Ebola virus (EBOV) 
antibodies.  The finalised report will then be submitted to ECBS, 2016 who will decide on the 
recommendations.  
Participation in the WHO collaborative study is conducted under the following conditions: 
 The data obtained in the collaborative study should not be published or cited before the 
formal establishment of the standard by WHO, without the expressed permission of the 
NIBSC Study organizer. 
 In order to address the immediate need for Ebola serology standards, participants are 
permitted to use the study samples for purposes that fall outside of the collaborative 
study.  To better inform the subsequent implementation of any standard, participants are 
encouraged to provide to the study organizer any information gained through their use of 
the study materials. THE CANDIDATE MATERIALS ARE PROVIDED TO 
PARTICIPANTS “AS IS”, WITHOUT ANY REPRESENTATION OR WARRANTY 
OF SATISFACTORY QUALITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 It is normal practice to acknowledge participants as contributors of data rather than co-
authors in publications describing the establishment of the standard. 
 Individual participant’s data will be coded and reported “blind” to other participants 
during the preparation of the study report, and also in subsequent publications. 
 Participants will receive a copy of the report of the study and proposed conclusions and 
recommendations for comment before it is further distributed. 
 Participants accept responsibility for safe handling and disposal of the materials 
provided. 
Deadline for completed results spread sheets is 6 weeks from receipt of study materials.  If it is not 
practicable to return results within 6 weeks, please inform Dianna Wilkinson.   
All completed results spread sheets should be returned electronically to:   
Dr Dianna Wilkinson 
Principal Scientist 
Viral Vaccines Section 
Division of Virology 
National Institute for Biological Standards and Control 
Blanche Lane, South Mimms 
Hertfordshire, EN6 3QG 
UK 
Tel. +44(0)1707 641314 
dianna.wilkinson@nibsc.org  
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Appendix 4 
Western blot analysis of study samples performed by Laboratory 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NZ – Zaire NP 
NS – Sudan NP 
GS – Sudan GP (two lanes) 
GZ – Zaire GP isoform 1 
GZ 1,2- Zaire GP isoform 1,2 
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Appendix 5 
Laboratory 10: Results of WHO EBOV Ab study CS570 
 
FANG ELISA Results 
Sample 93 showed high variability over the 4 days of ELISA testing (Appendix 5, Table 1). As 
the final concentration and endpoint titer result for Sample 93 was well above the ULOQ of our 
assay, a pre-dilution of 1:1024 was required to bring the sample within range of the assay. 
Testing of high titered samples with this assay has been shown to be precise and accurate with 
predilutions up to 1:128. Evaluation of larger dilution factors has not been performed. Because 
dilution of small volumes of sample into large volumes of assay diluent are required to pre-dilute 
to 1:1024, dilution bias may be a contributing factor in the high variability of sample 93. 
rVSV-ZEBOV GP PRNT Results 
Samples 93 and 94 both had poor titration curves in our PRNT assay on all 4 days they were 
tested.  Below is a graph depicting plaque counts from one day of running for samples 85, 92, 93 
and 94.  For samples 85 and 92, the titration was as expected with an increase in plaques as the 
sample became more dilute.  However, for samples 93 and 94, the plaque counts hovered around 
our 40% virus cutoff for many of the starting dilutions and did not increase until much later in 
the dilution series (see Appendix 5, Figure 1).  As such, the slope was relatively flat.  This 
resulted in significantly different PRNT60 titers being calculated for both of these samples (6590 
vs. 1806 for sample 93 and 690 vs. <20 for sample 94) when they passed the correlation 
coefficient criteria.  The other two days these samples failed these criteria because the plaque 
counts bounced above and below the virus control 40% cutoff.  Per our TSOP, correlation 
coefficient failures would be repeated, however, due to sample constraints, this was not possible.  
As such, there are only 2 data points for samples 93 and 94 that are available and these should be 
considered within the context of the flat titration seen on all days of testing.   It should be noted 
that although our assay does begin at a 1:10 dilution of sample, the PRNT60 results start at the 
1:20 dilution and exclude the initial 1:10 dilution due to a “plaque explosion phenomenon” that 
has been seen in our assay where there is an excessive number of plaques in the first dilution 
only. 
Figure 1. Graphs depicting the plaque counts of samples 85, 92, 93 and 94.  All samples had been pre-diluted 1:4 before 
being tested and as such, the values pertaining to the dilution of the sample on the x-axis should be multiplied by 4 for the correct 
dilution. 
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Appendix 5 continued 
 
Table 1. ELISA and PRNT Results for NIBSC Study CS570 Sample Panel. Each sample was tested on 4 separate run days in 
both the FANG ELISA and rVSV-ZEBOV GP PRNT assays. Samples with higher than expected variability are indicated in 
yellow.  The mean concentration, mean end point titer and mean PRNT60 are shown…. 
 
ELISA-PRNT Combined Overall Results 
Sample 
ID 
ELISA  PRNT 
Mean 
Conc. 
(EU/ml) 
Conc. %CV 
Mean 
Endpoint 
Titer 
Endpoint 
Titer %CV 
Mean %CV 
15/220 29458 13.1% 29257 33% 5802 30% 
38 16343 19.3% 19200 37% 1333 19% 
39 38 NA  50 NA  < 20 NA  
65 9758 23.8% 10971 28% 1609 7% 
85 10507 11.6% 12800 0% 1078 21% 
92 28561 22.4% 23040 25% 5989 14% 
93 250323 66.8% 332800 99% 4198 81% 
94 1189 14.3% 1200 47% 690 NA  
95 24873 19.0% 25600 0% 4402 24% 
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Appendix 6 
PsVNA50 and PsVNA80 data provided by Laboratory 13. 
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Appendix 7 
Summary of EIA and neutralisation assays provided by Laboratory 15. 
 
 
The FRNA assay, which detects neutralizing antibodies rather than GP specific antibodies, 
measured differing results based on criteria used (50 or 80% reduction). A FRNA50 measured 
four positive samples, three indeterminate samples, and two negative samples. When the 
neutralization criteria was more stringent (80%), four samples were FNRA positive and five 
were negative. A total of seven samples were positive for antibodies by ELISA and two samples 
were negative. 
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Appendix 8 
Laboratory 16 
Comparison of results obtained with the neutralisation assay against live Ebola virus Mayinga 
(lab code 16a) and EIA against inactivated Ebola virus Makona (16b). 
 
Method 16a. Endpoint titres for neutralisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Method 16b. EIA of collaborative study samples diluted 1/200. 
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Appendix 9 
Laboratory 17 
Data returned for samples assessed by Surface Plasmon Resonance. With <20 Resonance Units (RU) at the 1:40 
dilution, sample 39 scored overall negative. 
 Assay 1 Assay 2 
 Dilution  RU  RU 
WHO 
Reference 
Reagent-
NIBSC code 
15/220 
10x + 832.89 + 843.82 
20x + 442.95 + 447.07 
40x + 258.45 + 258 
80x + 163.63 + 167.05 
160x + 107.84 + 106.14 
     
38 
10x + 468.92 + 478.36 
20x + 314.75 + 316.65 
40x + 286.70 + 287.30 
80x + 187.98 + 185.03 
160x + 72.09 + 71.08 
     
39 
10x + 23.19 + 26.70 
20x + 15.63 + 16.73 
40x - 7.15 - 7.71 
80x - 5.03 - 5.13 
160x - 3.11 - 3.20 
     
66 
10x + 353.13 + 353.63 
20x + 192.93 + 192.57 
40x + 105.09 + 107.19 
80x + 72.18 + 73.17 
160x + 53.32 + 52.75 
     
85 
10x + 551.05 + 552.13 
20x + 331.42 + 335.94 
40x + 205.74 + 209.59 
80x + 125.23 + 127.28 
160x + 68.16 + 66.54 
     
92 
10x + 1038.24 + 1040.31 
20x + 599.62 + 605.21 
40x + 322.75 + 324.53 
80x + 195.13 + 196.59 
160x + 123.2 + 124.45 
     
93 
10x + 265.29 + 274.37 
20x + 193.73 + 194.07 
40x + 124.34 + 123.49 
80x + 80.56 + 79.45 
160x + 45.8 + 46.03 
     
94 
10x - 3.82 - 4.94 
20x - 3.01 - 3.62 
40x - -0.05 - 1.93 
80x - -0.08 - 1.59 
160x - 0.22 - 1.37 
     
95 
10x + 496.3 + 523.58 
20x + 286.25 + 291.48 
40x + 169.51 + 177.68 
80x + 118.02 + 120.39 
160x + 79 + 82.35 
     
Appendix 10 
Accelerated degradation data for the candidate WHO 1st International Standard 
Anti-EBOV Convalescent Plasma Pool-Sierra Leone (NIBSC 15/262). 
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Appendix 10 continued 
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Appendix 11 
Proposed instructions for use 
 
WHO International Standard 
1st WHO International Standard for EBOV antibodies 
NIBSC code: 15/262 
Instructions for use 
(Version 1.00, Dated ) 
1. INTENDED USE  
The 1st WHO International Standard for EBOV antibodies is intended to be used in the standardization of 
assays used in the detection and quantitation of EBOV antibodies 
2. CAUTION  
This preparation is not for administration to humans.  
The preparation contains material of human origin. The convalescent plasmas are confirmed PCR-
negative for EBOV and were solvent detergent-extracted prior to their development into the 1
st
 WHO IS. 
As with all materials of biological origin, this preparation should be regarded as potentially hazardous to 
health. It should be used and discarded according to your own laboratory's safety procedures. Such 
safety procedures should include the wearing of protective gloves and avoiding the generation of 
aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.  
3. UNITAGE  
1st WHO International Standard for EBOV antibodies an assigned unitage of 1.5 IU/mL. 
4. CONTENTS  
Country of origin of biological material: Sierra Leone 
Each ampoule contains the freeze-dried equivalent of 0.5 mL pooled convalescent plasma obtained from 
six Sierra Leone patients recovered from ebola virus disease (EVD). 
5. STORAGE  
15/262 should be stored at –20ºC on receipt. The contents of the ampoule should be reconstituted with 
0.1mL distilled water using safety precautions as described above.  
Please note: because of the inherent stability of lyophilized material, NIBSC may ship these 
materials at ambient temperature.  
6. DIRECTIONS FOR OPENING  
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider 
ampoule body 
Tap the ampoule gently to collect the material at the bottom (labelled) end. Ensure that the disposable 
ampoule safety breaker provided is pushed down on the stem of the ampoule and against the shoulder of 
the ampoule body. Hold the body of the ampoule in one hand and the disposable ampoule breaker 
covering the ampoule stem between the thumb and first finger of the other hand. Apply a bending force to 
open the ampoule at the coloured stress point, primarily using the hand holding the plastic collar.  
Care should be taken to avoid cuts and projectile glass fragments that might enter the eyes, for example, 
by the use of suitable gloves and an eye shield. Take care that no material is lost from the ampoule and 
no glass falls into the ampoule. Within the ampoule is dry nitrogen gas at slightly less than atmospheric 
pressure. A new disposable ampoule breaker is provided with each DIN ampoule.  
7. USE OF MATERIAL  
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution  
8. STABILITY  
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. 
Reference Materials should be stored on receipt as indicated on the label.  
NIBSC follows the policy of WHO with respect to its reference materials.  
9. REFERENCES  
 
10. ACKNOWLEDGEMENTS  
We gratefully acknowledge the important contributions of the collaborative study participants. We would 
also like to thank NIBSC Standards Production and Development for distribution of the candidate 
materials.  We also thank David Wood and Micha Nuebling of the WHO and participants of 
teleconferences for their support, guidance and advice. We also thank colleagues Maria Zambon, Angie 
Lackenby, Simon Carne, Pamela Saunders, Meera Chand and Kevin Brown at Public Health England, 
Colindale, UK for PCR testing of plasma samples. We also thank Steven A. Rubin, FDA/CBER, USA for 
facilitating the sample permits and shipments to laboratories in the USA. 
11. FURTHER INFORMATION  
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Further information can be obtained as follows;  
This material: enquiries@nibsc.org  
WHO Biological Standards:  
http://www.who.int/biologicals/en/  
JCTLM Higher order reference materials:  
http://www.bipm.org/en/committees/jc/jctlm/  
Derivation of International Units:  
http://www.nibsc.org/products/biological_reference_materials/frequently_ 
asked_questions/how_are_international_units.aspx  
Ordering standards from NIBSC:  
http://www.nibsc.org/products/ordering_information/frequently_asked_qu estions.aspx  
NIBSC Terms & Conditions:  
http://www.nibsc.org/terms_and_conditions.aspx  
12. CUSTOMER FEEDBACK  
Customers are encouraged to provide feedback on the suitability or use of the material provided or other 
aspects of our service. Please send any comments to enquiries@nibsc.org  
13. CITATION  
In all publications, including data sheets, in which this material is referenced, it is important that the 
preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and 
cited correctly.  
14. MATERIAL SAFETY SHEET Physical and 
Chemical properties  
Physical 
appearance: 
Freeze-dried  
Corrosive:  No  
Stable:  Yes  Oxidising:  No  
Hygroscopi
c:  
No  Irritant:  No  
Flammable:  No  Handling:See 
caution, Section 
2  
Other (specify):  Contains material of 
human origin.  
Toxicological properties  
Effects of inhalation:  Not established, avoid 
inhalation  
Effects of ingestion:  Not established, avoid 
ingestion  
Effects of skin 
absorption:  
Not established, avoid 
contact with skin  
Suggested First Aid  
Inhalation:  Seek medical advice  
Ingestion:  Seek medical advice  
Contact with eyes:  Wash with copious 
amounts of water. Seek 
medical advice  
Contact with skin:  Wash thoroughly with 
water.  
Action on Spillage and Method of Disposal  
Spillage of ampoule contents should be taken up 
with absorbent material wetted with an appropriate 
disinfectant. Rinse area with an appropriate 
disinfectant followed by water.  
Absorbent materials used to treat spillage should be 
treated as biological waste.  
15. LIABILITY AND LOSS  
In the event that this document is translated into another language, the English language version shall 
prevail in the event of any inconsistencies between the documents.  
Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of 
Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by 
the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this 
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document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of 
the Conditions.  
16. INFORMATION FOR CUSTOMS USE ONLY 
Country of origin for customs purposes*: United 
Kingdom  
* Defined as the country where the goods have been 
produced and/or sufficiently processed to be classed 
as originating from the country of supply, for example 
a change of state such as freeze-drying.  
Net weight: 0.5g per ampoule 
Toxicity Statement: Non-toxic  
Veterinary certificate or other statement if 
applicable.  
Attached: No  
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Proposed instructions for use 
WHO International Standard 
1st WHO International Reference Panel for EBOV antibodies NIBSC 
code: 16/344 
Instructions for use 
(Version 1.00, Dated ) 
1. INTENDED USE  
The 1st WHO International Reference Panel for EBOV antibodies is intended to be used in the 
assessment of assays used in the detection and quantitation of EBOV antibodies  
2. CAUTION  
This preparation is not for administration to humans.  
The preparation contains material of human origin. The panel consists of freeze-dried preparations of 
EVD convalescent plasma samples obtained from four patients and a negative control plasma. The 
convalescent plasmas are confirmed PCR-negative for EBOV and, along with the negative plasma, were 
solvent detergent-extracted prior to their development into the 1
st
 WHO International Reference Panel.  
As with all materials of biological origin, this preparation should be regarded as potentially hazardous to 
health. It should be used and discarded according to your own laboratory's safety procedures. Such 
safety procedures should include the wearing of protective gloves and avoiding the generation of 
aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.  
3. UNITAGE  
It is proposed that ARC sample is assigned a unitage of 1.1 IU/mL as calibrated against the IS. The 
NHSBT, NOR and INMI panel members have not been assigned a unitage. 
4. CONTENTS  
Country of origin of biological material: Italy, USA, UK, Norway 
Each ampoule contains the freeze-dried equivalent of 0.25 mL pooled convalescent plasma obtained 
from four patients recovered from ebola virus disease (EVD). 
5. STORAGE  
16/344 should be stored at –20ºC on receipt. The contents of the ampoule should be reconstituted with 
250 uL distilled water using safety precautions as described above.  
Please note: because of the inherent stability of lyophilized material, NIBSC may ship these 
materials at ambient temperature.  
 
6. DIRECTIONS FOR OPENING  
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider 
ampoule body 
Tap the ampoule gently to collect the material at the bottom (labelled) end. Ensure that the disposable 
ampoule safety breaker provided is pushed down on the stem of the ampoule and against the shoulder of 
the ampoule body. Hold the body of the ampoule in one hand and the disposable ampoule breaker 
covering the ampoule stem between the thumb and first finger of the other hand. Apply a bending force to 
open the ampoule at the coloured stress point, primarily using the hand holding the plastic collar.  
Care should be taken to avoid cuts and projectile glass fragments that might enter the eyes, for example, 
by the use of suitable gloves and an eye shield. Take care that no material is lost from the ampoule and 
no glass falls into the ampoule. Within the ampoule is dry nitrogen gas at slightly less than atmospheric 
pressure. A new disposable ampoule breaker is provided with each DIN ampoule.  
7. USE OF MATERIAL  
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution  
8. STABILITY  
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. 
Reference Materials should be stored on receipt as indicated on the label.  
NIBSC follows the policy of WHO with respect to its reference materials.  
9. REFERENCES  
  
10. ACKNOWLEDGEMENTS  
We gratefully acknowledge the important contributions of the collaborative study participants. We would 
also like to thank NIBSC Standards Production and Development for distribution of the candidate 
materials.  We also thank David Wood and Micha Nuebling of the WHO and participants of 
teleconferences for their support, guidance and advice. We also thank colleagues Maria Zambon, Angie 
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11. FURTHER INFORMATION  
Further information can be obtained as follows;  
This material: enquiries@nibsc.org  
WHO Biological Standards:  
http://www.who.int/biologicals/en/  
JCTLM Higher order reference materials:  
http://www.bipm.org/en/committees/jc/jctlm/  
Derivation of International Units:  
http://www.nibsc.org/products/biological_reference_materials/frequently_ 
asked_questions/how_are_international_units.aspx  
Ordering standards from NIBSC:  
http://www.nibsc.org/products/ordering_information/frequently_asked_qu estions.aspx  
NIBSC Terms & Conditions:  
http://www.nibsc.org/terms_and_conditions.aspx  
12. CUSTOMER FEEDBACK  
Customers are encouraged to provide feedback on the suitability or use of the material provided or other 
aspects of our service. Please send any comments to enquiries@nibsc.org  
13. CITATION  
In all publications, including data sheets, in which this material is referenced, it is important that the 
preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and 
cited correctly.  
14. MATERIAL SAFETY SHEET Physical and 
Chemical properties  
Physical 
appearance: 
Freeze-dried  
Corrosive:  No  
Stable:  Yes  Oxidising:  No  
Hygroscopi
c:  
No  Irritant:  No  
Flammable:  No  Handling:See 
caution, Section 
2  
Other (specify):  Contains material of 
human origin. 
Toxicological properties  
Effects of inhalation:  Not established, avoid 
inhalation  
Effects of ingestion:  Not established, avoid 
ingestion  
Effects of skin 
absorption:  
Not established, avoid 
contact with skin  
Suggested First Aid  
Inhalation:  Seek medical advice  
Ingestion:  Seek medical advice  
Contact with eyes:  Wash with copious 
amounts of water. Seek 
medical advice  
Contact with skin:  Wash thoroughly with 
water.  
Action on Spillage and Method of Disposal  
Spillage of ampoule contents should be taken up 
with absorbent material wetted with an appropriate 
disinfectant. Rinse area with an appropriate 
disinfectant followed by water.  
Absorbent materials used to treat spillage should be 
treated as biological waste.  
15. LIABILITY AND LOSS  
In the event that this document is translated into another language, the English language version shall 
prevail in the event of any inconsistencies between the documents.  
Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of 
Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by 
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the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this 
document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of 
the Conditions.  
16. INFORMATION FOR CUSTOMS USE ONLY 
Country of origin for customs purposes*: United 
Kingdom  
* Defined as the country where the goods have been 
produced and/or sufficiently processed to be classed 
as originating from the country of supply, for example 
a change of state such as freeze-drying.  
Net weight: 0.25g per ampoule 
Toxicity Statement: Non-toxic  
Veterinary certificate or other statement if 
applicable.  
Attached: No  
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